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1. INTRODUCTION
Mastitis, an infl ammation of  the mammary gland, is the most common 
disease affecting dairy cattle worldwide. Despite long-term research 
and the implementation of  preventive measures aimed at reducing the 
incidence of  clinical mastitis, its occurrence ranges between zero and 
200 cases per 100 cows per year (Schukken et al., 2001). The economic 
losses to the dairy industry due to clinical and subclinical mastitis can 
reach millions of  euros per year (Halasa et al., 2007).
Mastitis is a multi-factorial disease, which is related to the dairy cow’s 
immune status, mastitis-causing infectious agents and surrounding 
environment along with milking practices as the factors contributing 
to mammary gland infl ammation. In excess of  150 different pathogens 
have been associated with bovine mastitis. Bacteria entering via the 
teat canal cause intramammary infection (IMI) and the host responses 
with the developing infl ammation. Infl ammatory reaction can be mild, 
causing only an increase in the infl ammatory indicators of  the milk, 
defi ned as subclinical mastitis. Clinical mastitis characterized by visible 
abnormalities in the milk, in the udder, or in both, can be classifi ed as 
mild, moderate or severe (International Dairy Federation (IDF), 1999), 
whereas the severity of  clinical mastitis is based on the infl ammatory 
response. The exact reasons why in one cow subclinical and in another 
cow clinical mastitis with different severity will develop are not well 
understood. However, it is likely to be infl uenced by the pathogen 
involved as well as the immune status of  the cow (Sordillo, 2005). As 
mastitis is a dynamic process, subclinical mastitis can develop into the 
clinical form, and then return to the subclinical.
To identify the mastitis causing agents, microbiological diagnostic 
methods have been available and routinely used all over the world. 
Molecular diagnostic methods have advanced rapidly over the last decade, 
and the DNA-based mastitis diagnostic system has been introduced 
for the routine use (Koskinen et al., 2009). Due to the high sensitivity 
of  polymerase chain reaction (PCR)-based methods, often more than 
one udder pathogen has been detected from the milk samples and the 
interpretation of  laboratory results could be challenging (Koskinen et 
al., 2010).
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Clinical mastitis is a cow welfare issue and promt treatment of  clinical 
mastitis is of  great importance. The goal of  mastitis therapy is rapid 
elimination of  the infectious agent and prevention of  extensive tissue 
damage. Approximately 70% of  the antimicrobials used in dairy 
production are for treatment of  clinical mastitis (Thomson et al., 
2008), but the cure rates for clinical mastitis are not always satisfactory. 
Moreover, several antimicrobials and active substances have been used 
for the treatment of  clinical mastitis for more than fi fty years, but 
consensus on the most effi cient, safe and economical treatment is still 
lacking (Pyörälä, 2011). Widespread use of  antibiotics may promote 
the development of  antimicrobial resistance of  all bacteria that are in 
contact with antimicrobial agents (Prescott, 2007). International agencies 
including the Food and Agricultural Organization (FAO), World Health 
Organization (WHO), and World Organization for Animal Health (OIE) 
have stressed the need for fi nding alternative approaches to address the 
issue of  antimicrobial use in food animal production and its effect on 
the emergence of  antimicrobial resistance in human pathogens (FAO/
OIE, 2007) and the guidelines for prudent use of  antibiotics have been 
described by the European Veterinary Federation (FVE). 
In recent decades only broad-spectrum antibiotics have been used for 
treatment of  clinical mastitis in Estonia. For example, during the years 
2006-2009 fi fteen different combinations of  antibiotics were available 
for use in 18 intramammary preparations that were authorized by the 
Estonian State Agency of  Medicines, while according to the Finnish 
Medicines Agency only fi ve products for lactating cows were available 
in 2011. There are around 96,000 dairy cows in Estonia, whereas more 
than half  a million intramammary syringes for mastitis treatment are 
sold every year. Data on the distribution of  mastitis pathogens and 
antimicrobial resistance are still lacking in Estonia.
The average herd size is increasing in Estonia, and three-fourths of  the 
dairy cows are kept in herds with more than hundred cows (Estonian 
Animal Recording Centre, 2012). Tie-stall housing system had previously 
been prevalent, but in recent years extensive transition to loose-housing 
system has changed the calving conditions of  cows and heifers. Although 
clinical mastitis has frequently been observed at parturition, no data are 
available on udder health in freshly calved heifers and multiparous cows 
in Estonia. 
14
This dissertation focuses on different aspects of  clinical mastitis. In 
Study I, clinical mastitis pathogens and some risk factors in primiparous 
and multiparous dairy cows were evaluated. In Study II, the associations 
between the quantifi ed bacterial DNA and the local infl ammatory 
response were studied. The distribution of  udder pathogens and their 
antimicrobial resistance was evaluated in Study III, and treatment 
effi cacy of  penicillin-susceptible Gram-positive bacteria was evaluated 
in Study IV.
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2. REVIEW OF THE LITERATURE
2.1. Defi nition of  mastitis
Mastitis in dairy cattle is an infl ammation of  the mammary tissue of  the 
udder. The infl ammation of  the udder is mainly caused by intramammary 
infection (IMI), where different bacterial species enter the udder quarter 
via the teat canal. A case of  mastitis can be classifi ed as either subclinical 
or clinical mastitis. Subclinical mastitis is characterized by changes in 
milk composition and infl ammatory parameters in the milk, e.g. somatic 
cell count. In addition, milk N-acetyl-ß-D-glucosaminidase (NAGase) 
activity, lactate dehydrogenase content and electrical conductivity have 
been found as promising parameters for monitoring subclinical mastitis 
(Pyörälä, 2003). A threshold value of  100000 cells/ml has been suggested 
to determine whether a quarter is healthy or not (Hillerton, 1999; 
Krömker et al., 2001). Clinical mastitis is characterized by visual changes 
in the milk, udder, or even a cow. Clinical mastitis can be mild, moderate, 
or severe. Cows with mild clinical mastitis typically have abnormalities 
in the milk such as clots and fl akes with little or no swelling of  the gland 
or systemic illness. Cows with severe clinical mastitis typically have a 
sudden onset of  udder infl ammation, abnormal milk, and systemic signs 
such as fever, increased heart rate, dehydration, weakness and depression 
(IDF, 1999).
2.2. Clinical mastitis in primiparous and multiparous dairy cows
The incidence of  clinical mastitis in dairy cows has been investigated in 
numerous studies all over the world. The occurrence of  clinical mastitis 
on dairy farms in England, Czech Republic, and Ireland was 47, 53, and 
54 cases per 100 cows per year, respectively (Wolfova et al., 2006; Bradley 
et al., 2007; More et al., 2012). The mean clinical mastitis incidence in 
Canada was 23 cases per 100 cows per year (Riekerink et al., 2008). 
Although replacement heifers are generally expected to have good udder 
health, the IMI has been detected at least as early as breeding age (8-19 
months), and the prevalence of  IMI of  heifers was the highest during 
the periparturient period (Pankey et al., 1991; Matthews et al., 1992; Fox 
et al., 1995, Nickerson et al., 1995). A higher risk of  developing clinical 
mastitis occurs also during early lactation, where three-fourths of  the 
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cases of  clinical mastitis in primiparous dairy cows occur within the 
fi rst 30 days postpartum, most commonly chronologically closer to 
parturition (Jonsson et al., 1991; Barnoiun and Chassagne, 2001; Persson 
Waller et al., 2009). A nested case-control study in Norway showed that 
5% (6,410 out of  128,027) of  cases of  clinical mastitis were treated 
in fi rst-calving heifers (Waage et al., 1999). In Finland, the frequency 
of  treatments for heifer mastitis from one week before to one week 
after calving was 3.9% for Ayrshires and 5.6% for Friesians (Myllys and 
Rautala, 1995). One year prevalence of  clinical mastitis was 9.1% among 
the heifers from ten German dairy herds (Tenhagen et al., 2009), and 
8.1% in a Dutch study (van den Borne et al., 2007). In a study performed 
in the Netherlands, the rate of  clinical mastitis around parturition was 
found to be higher in heifers (>30%) compared to older cows (13%) 
(Barkema et al., 1998).
The distribution of  clinical mastitis pathogens varies between regions, 
countries, and even between farms. For example, 60.2 % of  the cases 
of  clinical mastitis in Israel have been caused by Escherichia coli (E. coli), 
whereas in Norway Staphylococcus aureus (S. aureus) is the most common 
clinical mastitis pathogen (Shpigel et al., 1998; Osterås et al., 2006). 
Observational studies from the United States, Canada, and the United 
Kingdom have reported coliforms, Streptococcus uberis (Str. uberis) and S. 
aureus to be the most frequently isolated bacteria from clinical mastitis 
(Wilson et al., 1997; Reksen et al., 2006; Riekerink et al., 2008). Coagulase-
negative staphylococci (CNS) are showing increase in Finland (Pitkälä et 
al., 2004). The most common CNS in bovine mastitis are S. chromogenes, 
S. simulans, S. xylosus and S. epidermidis. S. hyicus was described as the 
most pathogenic CNS (Myllys, 1995), and more common fi nding among 
the clinical mastitis, while S. epidermidis was the major pathogen isolated 
from subclinical mastitis cases (Persson Waller et al., 2011). Streptococcus 
agalactiae (Str. agalactiae) has been largely eradicated from herds in Europe, 
while in the studies from the United States, 7.7% and 13.1% of  samples 
were reported to contain Str. agalactiae (Wilson et al., 1997; Makovec and 
Ruegg, 2003). The main subclinical mastitis pathogens in Germany, the 
Netherlands and France are CNS, Corynebacterium bovis (C. bovis), and S. 
aureus (Tenhagen et al., 2006; Piepers et al., 2007; Botrel et al., 2009). 
Despite the fact that primiparous cows may benefi t from separate 
grouping and management conditions prior to calving, the causative 
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pathogens of  clinical mastitis are the same that cause clinical mastitis 
in multiparous dairy cows (Oliver and Mitchell, 1983; Jonsson et al., 
1991, Tenhagen et al., 2009; Persson Waller et al., 2009). Among the 
primiparous dairy cows CNS, S. aureus, Str. dysgalactiae, and coliforms 
have been found the major pathogens causing clinical mastitis (Trinidad 
et al., 1990; Myllys, 1995; Waage et al., 1999). From CNS, S. chromogenes 
predominates in heifers around calving, whereas S. simulans predominates 
in the subsequent lactations (Taponen et al., 2006; Thorberg et al., 2009).
2.3. Risk factors for clinical mastitis in primiparous dairy cows
The transition phase, typically defi ned as the period from three weeks 
before to three weeks after parturition, is viewed as a critical time in the 
lactation cycle of  a dairy cow. During this period, the cow experiences a 
series of  nutritional, physiological and social changes which render the 
cow more susceptible to infectious and metabolic diseases (Goff  and 
Horts, 1997). In general, management factors at the herd level, including 
housing, feeding and milking systems as well as pathogens surrounding 
the cows, increase the incidence of  clinical mastitis in both primiparous 
and multiparous cows (Schukken et al., 1990; Valde et al., 1997; Barkema 
et al., 1999; Aland, 2003). The presence of  udder odema at calving, blood 
in the milk, and milk leakage were associated with increased risk of  
postpartum clinical mastitis of  primiparous dairy cows (Waage, 2001). A 
recent study by German researchers showed that loose-housing systems 
during pregnancy (as opposed to tie-stalls), juvenile intersucking, clinical 
mastitis during the fi rst week after calving, teat diameters <18 mm, and 
employing organic bedding material in the stables before calving were 
associated with subclinical mastitis measured at 41days in milk (DIM) 
(Krömker et al., 2012). An open teat canal before parturition has been 
found to be an important risk factor in the etiology of  heifer mastitis 
and the incidence of  clinical mastitis during the fi rst lactation has been 
infl uenced by the duration of  IMI prior to parturition (Krömker and 
Friedrich, 2009). Despite the region, Holstein dairy heifers seem to be 
more susceptible to clinical mastitis than other breeds (Parker et al., 2007; 
Nyman et al., 2009; Persson Waller et al., 2009).
Poor hygiene in farm facilities during the dry and the calving period is 
one of  the risk factors for mastitis, especially for pathogens like E. coli, 
Str. uberis, and T. pyogenes originating from the environment. In addition, 
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there are several possible sources of  S. aureus that may cause clinical 
mastitis before and after parturition of  heifers. The risk of  S. aureus IMI 
depends on the length of  time the heifers are housed together with older 
cows and the proportion of  S. aureus infected cows in the herd (Bassel 
et al., 2003). In addition, early spread of  S. aureus from older cows to 
fi rst lactating cows may happen during the fi rst milking (Tenhagen et 
al., 2009), when older cows with infected udder are kept together with 
freshly calved heifers. Colonization of  S. aureus in the teat skin or in the 
inguinal area, accompanied by transmission with fl ies has been found 
to be another source of  S. aureus infection (Sears and McCarthy, 2003).
2.4. Mastitis diagnostics
2.4.1. Microbiological diagnosis of mastitis
Early diagnosis of  mastitis is of  the utmost importance due to the high 
costs of  disease. Diagnostic methods have been developed to check the 
quality of  the milk through detection of  mammary gland infl ammation 
and diagnosis of  the infection and its causative pathogens. Although 
more than 150 different bacterial species have been isolated from 
the milk of  infl amed udder, mastitis is usually caused by one primary 
pathogen (Watts and Yancey, 1994), and approximately 10 bacterial 
species or species groups account for more than 95% of  all clinical and 
subclinical infections (Makovec and Ruegg, 2003; Tenhagen et al., 2006; 
Bradley et al., 2007).
For a long time, the golden standard for identifi cation of  bacterial species 
in case of  clinical and subclinical mastitis was conventional microbiology. 
Over the last decade, polymerase PCR-based methods have been 
introduced for detection of  single mastitis pathogens (Phuektes et al., 
2001; Gillespie and Oliver, 2005; Graber et al., 2007). Recently, very high 
analytical accuracy was reported for a real-time PCR-based reagent kit 
capable of  detecting 11 important IMI species/species groups and the 
beta-lactamase gene (PathoProof  TM Mastitis PCR Assay, Thermo Fisher 
Scientifi c, Espoo, Finland) based on a large collection of  culture isolates 
(Koskinen et al., 2009).
Molecular methods have several advantages compared with conventional 
methods. PCR-based methods are more sensitive than conventional 
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bacteriology, and more species are detected in the sample (Koskinen et 
al., 2010). Conventional bacterial culturing is relatively slow to perform, 
as incubation of  primary cultures often requires 48 h (or up to 72 h) 
to complete, and additional confi rmation tests are also time-consuming 
(National Mastitis Council, 2004). PCR-based methods provide good 
accuracy and speed for analysing milk samples (Koskinen et al., 2009). 
According to the literature, no bacterial growth is detected in at least 20 
to 30% of  milk samples taken from udder quarters with clinical mastitis 
(Hogan et al., 1989; Nevala et al., 2004; Bradley et al., 2007). PCR method 
provides a bacteriological diagnosis for almost half  of  the cases where 
conventional culture results are negative (Taponen et al., 2009).
In Estonia, PCR-based mastitis diagnostics was implemented in 2011. In 
Finland already over 80 % of  the milk samples are investigated using a 
commercial PCR test (PathoProof™, Thermo Fisher Scientifi c) and the 
same trend can be seen elsewhere.
2.4.2. Infl ammatory reaction during clinical mastitis and an 
acute phase response
The incidence of  mastitis increases when the defense mechanisms of  
the mammary gland are impaired. The mammary gland is protected by 
innate and specifi c immunity. The innate immunity is not pathogen-
specifi c and infl ammatory responses are either present or are activated 
quickly during early stages of  infection (Rainard and Riollet, 2006). Those 
primary defence mechanisms of  the mammary gland are mediated by 
the physical barrier of  the teat end, macrophages, neutrophils, natural 
killer cells, and by certain soluble factors (Sordillo, 2005). The specifi c or 
acquired immune system recognizes specifi c determinants of  a pathogen 
that activate selective elimination. Recognition of  pathogenic factors is 
mediated by antibody molecules, macrophages, and several lymphoid 
populations.
The infl ammatory reaction is a series of  complex physiological events 
occurring in the host after tissue injury or infection. The severity of  
clinical mastitis depends on the number of  bacteria entering via the teat 
canal, access of  the microbe to the target tissue, virulence of  the strain 
and immunity of  the host (Burton and Erskine, 2003).
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Tissue injury due to infl ammation causes acute phase response (APR), 
which most commonly begins by the release of  infl ammatory mediators 
from tissue macrophages or blood monocytes that gather at the site of  
damage (Baumann and Gauldie, 1994; Koj, 1996). Also, the mammary 
epithelium has been suggested to be a site of  synthesis of  cytokines and 
other infl ammatory mediators (Persson Waller et al., 1997). A prominent 
event in the APR is the increase production of  acute-phase proteins 
(APP) in liver. APP are heterogeneous group of  proteins with different 
functions. In general, APP prevents spread of  infectious agents, induce 
anti-infl ammatory cytokines, promote healing by supplying nutrients to 
destroyed tissue, and restore homeostasis (Murata et al., 2004). Two of  
these proteins, haptoglobin (Hp) and serum amyloid A (SAA), contribute 
to host defense through antibacterial activity and play a signifi cant role 
in the early response to invasion of  mammary tissues by pathogenic 
bacteria. Haptoglobin is diffused from blood into the milk, but it also 
originates from milk leukocytes and the mammary gland epithelium (Hiss 
et al., 2004). Serum amyloid A is secreted by hepatocytes and, in addition, 
the mammary gland epithelium appears to secrete a mammary gland-
specifi c isoform mammary-associated serum amyloid A 3 (MSAA3) 
milk amyloid A (MAA)(Eckersall et al., 2001). MAA and Hp synthesized 
in udder have been suggested to be sensitive and potentially suitable 
markers for detection of  mastitis and evaluation of  udder infl ammation 
severity during clinical mastitis (Eckersall et al., 2001, Eckersall et al., 
2006; Pyörälä et al., 2011).
NAGase is an intracellular, lysosomal enzyme that is released into milk 
from neutrophils during phagocytosis and cell lysis, but also from 
damaged epithelial cells, indicating udder tissue destruction (Kitchen et 
al., 1984). Milk NAGase activity correlates very closely with SCC and 
can be analysed also from frozen milk samples (Kitchen et al., 1984).
Local APR in the udder has been studied using experimental models, 
where E. coli (Hyvönen et al., 2006; Suojala et al., 2008; Larsen et al., 2010) 
or staphylococci (Grönlund et al., 2003; Simojoki et al., 2009) have been 
inoculated into the udder quarter. Results from these studies indicated 
that coliform bacteria caused a larger increase in concentrations of  APP 
in milk, compared to CNS and S. aureus. Studies on the innate immune 
response in naturally occurring clinical mastitis are less common. Wenz et 
al. (2010) found that the concentration of  Hp in milk was the highest in 
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E. coli mastitis as compared with mastitis caused by either environmental 
streptococci or CNS. A larger study conducted by Pyörälä et al. (2011) 
concluded that the concentrations of  APP and NAGase activity in milk 
varied according to isolated mastitis pathogens, where concentrations 
of  APP were the highest in case of  E. coli mastitis compared to other 
mastitis pathogens, streptococci and S.aureus. Infl ammatory responses 
of  MAA and Hp were very mild in CNS mastitis (Pyörälä et al., 2011).
2.5. Treatment of  clinical mastitis
Knowledge of  clinical mastitis severity, culture-based therapy and 
treatment effi cacy are essential in effectively and effi ciently managing 
mastitis cases (Roberson, 2012). The primary objective of  antibacterial 
treatment of  clinical mastitis is rapid elimination of  the infectious agent 
to prevent serious tissue damage and maintain further milk production 
(Constable et al., 2008). In attempts to improve the response to treatment, 
various classes of  antimicrobial compounds, drug combinations, 
application routes, and treatment durations have been investigated 
(Hillerton and Kliem, 2002; Serieys et al., 2005; Bradley and Green, 
2009). Therefore it is not always possible to differentiate between the 
effect of  the active compound and the effect of  the commercial product 
and its route or dose of  administration (Barkema et al., 2006). 
In antimicrobial treatment of  animal infections such as mastitis, targeting 
the treatment towards the causing agents is recommended in global 
prudent use guidelines (OIE, 2012). Moreover, the risk for emergence 
of  resistance among bacteria is higher if  blanket therapy is used. A 2008 
study of  165 clinical mastitis cases found that the treatment of  nearly 
50% of  the cases was unnecessary (no bacterial growth) or inappropriate 
(in vitro resistant isolates) (Roberson, 2008). If  the causative agent of  
infection is susceptible to the so-called fi rst-line antimicrobials, such 
as agents with a relatively narrow spectrum, including benzylpenicillin, 
they should be used for treatment (Constable et al., 2008). However, 
in the majority of  countries, the treatment of  mastitis remains reliant 
on the routine use of  combinations of  several active substance or 
broad-spectrum antimicrobials (Ruegg, 2010). Selection pressure for the 
development of  antimicrobial resistance among bacteria is greater when 
broad-spectrum agents are used (Hunter et al., 2010).
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2.5.1. Antibiotics used in treatment of clinical mastitis
According to Ziv (1980), the ideal antibacterial for the treatment of  
clinical mastitis would have a low minimum inhibitory concentration 
(MIC) against the udder pathogens and a high bioavailability from the 
intramuscular injection sites. The antibacterial agent would be weakly 
basic or non-ionized in serum, and suffi ciently lipid-soluble. Also, a 
low degree of  protein binding and long half-life to maintain activity in 
infl ammatory secretions, are necessary characteristics of  an effective 
antibiotic. For example, intramuscularly injected penicillin G, which is a 
weak acid, penetrates poorly into the mammary gland, but due to very 
low MIC values of  susceptible organisms, therapeutic concentration 
can be achieved in milk. Pharmacokinetics and pharmacodynamics of  
different antibiotics greatly affect their suitability for mastitis treatment. 
The antimicrobial should preferably have bactericidal action, as 
phagocytosis is impaired in the mammary gland (Constable and Morin, 
2003). Activity of  broad-spectrum antibiotics like oxytetracycline and 
trimethoprim-sulfonamides has been shown to be reduced in milk 
(Louhi, 1992). Almost all active substances for mastitis treatment 
work as time-dependent antimicrobials. The effi cacy is maximized by 
keeping the concentration of  drug at the site of  infection above the 
level necessary to inhibit microbial growth as long as possible between 
two administered doses of  the drug. The concentration-dependent 
antibiotics, fl uoroquinolones, have been used for the treatment of  E. coli 
mastitis as the high concentration of  the antibiotic increases the rate of  
killing rapidly proliferating bacteria (Prescott, 2007).
Broad-spectrum antibiotics like fl uoroquinolones, ceftiofur, cefquinome 
and oxytetracycline have been used or recommended for the treatment 
of  E. coli mastitis. At the same time, antibiotic treatment of  E. coli mastitis 
is still controversial. Cows with severe clinical mastitis and in the stage 
of  bacteremia would be suggested to be treated with antimicrobials 
for 3-5 days (Roberson, 2012). Some studies using enrofl oxacin or 
cephalosporins have shown faster elimination of  bacteria and increased 
survival (Erskine et al., 2002b; Rantala et al., 2002; Poutrel et al., 2008), 
but other studies did not support this hypothesis (Wenz et al., 2005; 
Suojala et al., 2010;). Cure rates for mastitis caused by penicillin-resistant 
S. aureus isolates seem to be inferior to those of  mastitis due to penicillin-
susceptible isolates (Sol et al., 2000; Taponen et al., 2003a).
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Different antibacterial agents have been used in clinical trials for the 
evaluation of  treatment effi cacy. The bacteriological cure rates of  clinical 
mastitis caused by Gram-positive bacteria have ranged between 15.4 and 
91.6% (Table 1).
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1 Penicillin susceptible bacteria
2 Penicillin resistant bacteria
3 IM - intramuscular treatment; IMM - intramammary treatment
4- experimental study
2.5.2. Treatment route
The pharmacological goal of  antimicrobial therapy is to attain effective 
concentration of  the drug at the site of  infection. The most common 
route of  administration of  antimicrobials in mastitis is the intramammary 
route (Gruet et al., 2001). Systemic (parenteral) treatment has been 
suggested to be more effi cient than intramammary (IMM) treatment, 
due to better distribution of  the drug throughout the mammary gland 
(Ziv, 1980; Franklin et al., 1984). The parenteral antibacterial treatment 
of  mastitis is widely used in the Nordic countries (Grave et al., 1999; 
Thomson et al., 2008). 
There are three potential therapeutic targets or pharmacological 
compartments for mastitis: the milk and the mammary gland epithelial 
layer, the mammary gland parenchyma, and the cow. The important 
question is whether the antibiotic should accumulate in the milk or in 
the udder tissue. Streptococci, CNS and corynebacteria are known to 
remain in the milk compartment, therefore IMM treatment could be a 
preferable choice (Erskine et al., 2003). The advantage of  the IMM route 
would be high concentrations of  the substance achieved in the milk and 
low consumption of  the antimicrobial, as the drug is directly infused 
into the quarter (Moretain et al., 1989). The disadvantage is distribution 
of  the antimicrobial throughout the udder and the risk of  infecting 
the quarter when infusing the product via the teat canal (Ehinger and 
Kietzmann, 2000). Parenteral treatment strategies, either used alone or 
in combination with IMM treatment, have been suggested in case of  S. 
aureus mastitis (Erskine et al., 2003).
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2.6. Antimicrobial resistance of  udder pathogens causing clinical 
mastitis
Resistance of  bacteria to antibacterial drugs was fi rst reported soon after 
antibacterial drugs were accepted for use in both human and veterinary 
medicine. The two main factors involved in the development of  antibiotic 
resistance in bacteria are the selective pressure by the use of  antibiotics 
and the presence of  resistance genes (Witte, 2000). Resistance that is 
acquired by horizontal transfer of  resistance genes can become rapidly 
and widely disseminated either by clonal spread of  the resistant strain 
itself  or by further genetic exchanges between the resistant strain and 
other susceptible strains (Chambers, 2001).
National studies of  mastitis prevalence provide important information 
through the monitoring of  national udder health status. For instance, 
national guidelines for the prudent use of  antibiotics have been available 
in Finland (EVIRA, 2009). In recent decades, only broad-spectrum 
antibiotics have been used for the treatment of  clinical mastitis in 
Estonia. According to the Estonian State Medical Agency, 15 different 
combinations of  antibiotics are available for use in 18 intramammary 
preparations that have been authorized.
Approximately 80% of  all antimicrobials used in dairy production are 
used to treat clinical or subclinical mastitis (Pol and Ruegg, 2007). Myllys 
et al. (1998) have reported upward trend over time in resistance among 
mastitis pathogens, whereas others do not agree with that statement 
(Erskine et al., 2002a). A large-scale study was carried out by Makovec and 
Ruegg (2003) to investigate the trends of  development of  antimicrobial 
resistance over a 7-year period. In all Gram-positive pathogens, the 
percentage of  isolates resistant to beta-lactam antimicrobials decreased 
signifi cantly over time, whereas the percentage of  Staphylococcus 
spp. isolates and resistance to tetracycline and macrolides increased 
signifi cantly.
For in vitro antimicrobial susceptibility testing several different methods 
are available, among which agar diffusion and broth microdilution 
are most frequently used. In both methods bacteria are classifi ed as 
resistant, intermediate or susceptible to target antibiotics. Although 
there is a certain correlation between the diameter of  zone of  growth 
of  inhibition and susceptibility of  the bacteria, it is not appropriate to 
convert diameter values into the MICs (Schwarz et al., 2009).
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The main feature of  staphylococci is production of  β-lactamase, which 
causes hydrolysis and destruction of  the β-lactam ring of  penicillin 
rendering it ineffective. The number β-lactamase positive S. aureus 
strains have been varied a lot in different studies carried out in many 
countries. Studies from France, Finland, Argetina and the UK reported 
high prevalence of  penicillin-resistant S. aureus (36.2%, 52.1%, 40,3% 
and 56%, respectively) (Guerin-Faublee et al., 2003; Pitkälä et al., 2004; 
Gentilini et al., 2000; Bradley et al., 2007), whereas low numbers of  
resistant strains (4 to 9%) were found in Norway and in Canada (NORM/
NORMVET 2003; Saini et al., 2012). De Oliveira et al. (2000) compared 
the data from 11 countries, where β -lactamase resistance varied from 
4% in Norway to 76% in Ireland. Compared with S. aureus, CNS are 
more often resistant to several antibiotics (Taponen and Pyörälä, 2009). 
For example, in Finland, reported prevalence of  β-lactamase positive S. 
aureus was 13% and β-lactamase positive CNS 23% (Nevala et al., 2004). 
In Sweden, among the cases of  clinical mastitis 7.1% of  S. aureus and 
12.5% of  CNS produced β-lactamase (Bengtsson et al., 2009), despite 
several decades of  using penicillin as the antibiotic of  fi rst choice. 
Other classes of  antibiotics used in the treatment of  staphylococcal 
clinical mastitis are macrolides and lincosamides. Macrolide and 
lincosamide antibiotics have common targets in the bacterial ribosome, 
and organisms that are resistant to one class can be resistant to the 
other class (Berger-Bächi, 2002). Resistance against those antimicrobials 
generally ranges between 0 and 17% (Erskine et al., 2002a; SVARM 
2004; Bengtsson et al., 2009), however, high levels of  resistance have 
been described in China, being 93% for erythromycin and 36.1% for 
clindamycin (Wang et al., 2008).
Mastitis caused by streptococci has remained susceptible to β –lactams 
(Myllys et al., 1998; Pitkälä et al., 2004). Studies from France and Germany 
revealed that all Str. dysgalactiae and Str. agalactiae strains were susceptible 
to β-lactams, whereas Str. uberis strains showed an elevated penicillin G 
MIC (Haenni et al., 2010; Minst et al., 2012). Resistance to macrolides and 
lincosamides ranged between 0 and 20% in different studies (FINRES-
Vet, 2005-2006; SVARM, 2007; MARAN, 2008). 
Cephalosporins are commonly used in the treatment of  clinical E. coli 
mastitis due to high antibacterial activity against coliforms. Resistance 
against cephalosporins has been highlighted in recent years, and 
28
monitoring of  extended-spectrum β-lactamases (ESBL) producing E.coli 
was started in the national antimicrobial resistance programs. In case of  
clinical mastitis ESBL producing E. coli was not detected in Sweden, 
Finland, Norway and Canada, whereas low prevalence (0.4%) has been 
found among E. coli strains in France (Dahmen et al., 2013; SVARM, 
2011; EVIRA, 2012; Saini et al., 2012). Data from the U.S. showed higher 
resistance to cephalosporins, but the disk-diffusion method was used 
in this report. The highest resistance against tetracycline, from 14.8 to 
37.3%, has been reported (Makovec and Ruegg, 2003; MARAN, 2008; 
Saini et al., 2012). E. coli resistance against ampicillin has ranged between 
7 and 45.5% (Hendriksen et al., 2008)
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3. AIMS OF THE STUDY
1. Identify common udder pathogens of clinical mastitis in primiparous 
and multiparous cows on the day of calving in Estonia (I).
2. Evaluate mastitis occurrence in primiparous cows in different housing 
systems, and investigate whether it is affected by the time interval 
between movement of heifers to their calving facility and their day 
of calving (I).
3. Investigate associations between different quantities of bacterial 
DNA detected using a PCR based method, and concentrations of 
APP and NAGase activity in the milk in naturally occurring clinical 
mastitis (II).
4. Compare APP concentrations and NAGase activity in the milk from 
cows with clinical mastitis caused by different udder pathogens  (II).
5. Estimate the distribution of udder pathogens and their antibiotic 
resistance in Estonia over the period 2007–2009 (III).
6. Compare the effi cacy of intramammary and parenteral treatment 
with benzylpenicillin of bovine clinical mastitis caused by penicillin-
susceptible Gram-positive bacteria (IV).
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4. MATERIALS AND METHODS
4.1. Study design
To evaluate the occurrence of  clinical mastitis in heifers on the day 
of  calving (Study I), a case-control study was designed. Eleven dairy 
herds with more than 100 cows and 50 replacement heifers calving per 
year were included. All heifers (n = 1,063) that calved during the one-
year period were eligible for inclusion. Heifers with clinical mastitis on 
the day of  calving were included as cases (n = 68), and the remaining 
freshly calved heifers (n = 995) were controls. Heifers on each farm were 
moved from their rearing facility to the milking farm according to the 
availability of  space. The stall-length and type of  management system 
(free-stall or tie-stall), the number of  days between the day of  transfer 
of  the heifer to the cowshed and the day of  calving, were recorded. 
In Studies II and IV, milk samples from cows diagnosed as having clinical 
mastitis were collected from four herds, in the practice area of  the large 
animal clinic of  the Estonian University of  Life Sciences. All farms were 
with loose-housing system and with parallel milking parlour. All herds 
were milked three times a day. The mean herd bulk milk somatic cell 
count per month ranged between 198,000-408,000 cells/ml during the 
study period. 
A retrospective study (Study III) was based on an analysis of  milk samples 
submitted to the Estonian National Veterinary Laboratory over a three-
year period from 2007 to 2009. Quarter milk samples were collected 
from cows on Estonian dairy farms by local veterinarians or farmers.









No. of milk 
samples
I 2004-2005 11 259 (200; 350) 7625 (5822; 9130) 3418
III 2007-2009 274 86.7 (2; 1800) 8204
II; IV 2007-2009 4 300-1000 8387 (6900; 9850) 281
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4.2. Defi nition of  clinical mastitis (I-IV)
According to the defi nition of  clinical mastitis in the Bulletin of  the 
IDF No 32 (1999) at least some visible signs are present in the udder or 
in the milk. If  the milk from a quarter had abnormal viscosity (watery, 
thicker than normal), color (yellow, blood-tinged), or consistency (fl akes, 
clots), clinical mastitis was diagnosed, and samples from diseased udder 
quarters were collected for bacteriological examination. Clinical mastitis 
was diagnosed and milk samples were collected by local trained farm 
personnel or veterinarians. Normal milk appearance, together with a 
positive California Mastitis Test result (score greater than 1), were used 
to make a diagnosis of  subclinical mastitis.
Additionally, in Studies II and IV the severity classifi cation was used. 
Systemic and local signs were recorded and categorized using a 3-point 
scale as follows: (1) mild clinical mastitis: milk from a quarter had 
abnormal viscosity (watery or thicker than normal), color (yellow or 
blood-tinged), or consistency (fl akes or clots), but no udder swelling 
or systemic signs; (2) moderate clinical mastitis: similar to mild clinical 
mastitis, but with the addition of  visible or palpable changes in the udder 
(swelling or pain) without systemic signs; and (3) severe clinical mastitis: 
both local and systemic signs (fever above 39.2°C).
4.3. Collection of  milk samples (I-IV)
Once clinical mastitis was diagnosed, aseptic quarter milk samples were 
taken. Before sampling, the teat end was cleaned with 70%-ethanol 
swabs and allowed to dry. After discarding a few streams of  milk, 2-7 ml 
of  milk samples were collected in sterile 10 ml plastic tubes. All collected 
milk samples were cooled in the refrigerator and frozen at -20°C until 
further investigation (Study I). In Studies II and IV, all collected milk 
samples were frozen after preliminary on-farm bacteriology. In Study 




4.4.1. Conventional bacteriology (I, III, IV)
In Studies I and III, bacterial species were cultured and identifi ed 
using accredited methodology based on the National Mastitis Council 
standards (2004) in the Estonian Veterinary and Food Laboratory. 
From each sample, 0.01 ml of  milk was cultured on blood-esculin agar 
and incubated for 48 h at 37°C. The plates were examined after 24 and 
48 h of  incubation. A minimum of  fi ve colonies of  the same type of  
bacterium was recorded as bacteriologically positive, and growth of  more 
than two types of  bacterial colonies was categorised as mixed growth. 
No bacterial growth was recorded when fewer than fi ve colony-forming 
units were detected during 48h of  incubation.
In Study IV, on–farm the preliminary on-farm bacteriology was used 
to differentiate between Gram-positive and Gram-negative bacteria. 
Ten μl of  milk was streaked onto each section and plates were cultured 
for 12-24h. Bacterial growth was evaluated at fi rst on the blood-esculin 
agar and then on the McConkey agar (the media for detection of  
Gram-negative bacteria) or on the salt-mannitol agar (the media for 
detection of  staphylococci). After detection of  staphylococci, penicillin 
resistance indicated by β-lactamase production was determined using a 
chromogenic nitrocefi n test (Becton Dickinson Microbiology Systems, 
Cockeysville, MD, USA) (NCCLS 2002). 
4.4.2. Real-time PCR assay (II, IV)
In Studies II and IV, a commercial real-time PCR test kit (Patho Proof  
Mastitis PCR Assay, Thermo Fisher Scientifi c, Espoo, Finland) was 
used for direct analysis of  all milk samples. The kit protocol involved 4 
separate multiplex real-time PCR reactions, which targeted 11 bacterial 
species and groups (covering more than 25 mastitis-causing species 
in total): Staphylococcus spp. (including S. aureus and all relevant CNS 
species), Enterococcus spp. (including Enterococcus faecalis and Enterococcus 
faecium), C. bovis, E. coli, Str. dysgalactiae, Str. agalactiae, Str. uberis, Trueperella 
(formerly Arcanobacterium) pyogenes / Peptoniphilus indolicus (Yassin et al., 
2011), Klebsiella spp. (including K. oxytoca and K. pneumoniae), and Serratia 
marcescens. The PCR assay also detects the staphylococcal beta-lactamase 
gene blaZ coding for penicillin resistance. The tests were performed in 
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accordance with the user manual, and described by Koskinen et al. (2010). 
Based on the cycle threshold (Ct) values, the bacterial DNA quantity in 
each targeted bacterial species was grouped into three classes: +, ++, or 
+++, according to the manufacturer’s manual. 
4.4.3. Analytical methods for determination of infl ammatory 
response in milk
4.4.3.1. Determination of milk amyloid A and haptoglobin (II)
All analyses for determination of  acute phase protein were performed 
at the Institute of  Veterinary Medicine and Animal Sciences, Estonian 
University of  Life Sciences. The concentration of  MAA in milk was 
determined using a commercial ELISA kit (Phase MAA Assay Kit, 
Tridelta Development Ltd, Ireland). Milk samples were initially diluted 
to 1:500. If  the concentration was above the range of  a standard curve, 
they were further diluted as necessary. For very high MAA values, milk 
samples were diluted up to 1:10000 (maximum concentration 1500 
mg/l). A 1:100 dilution was used (minimum concentration 0.94 mg/l) 
for very low values. Intra- and inter-assay coeffi cients of  variation (CV) 
were <13% and <12%, respectively.
Milk Hp concentrations (mg/l) were determined by a method based on 
the ability of  Hp to bind to haemoglobin (Makimura and Suzuki, 1982) 
and using tetramethylbenzidine as a substrate (Almsegeest et al., 1994). 
The assay is originally aimed to determine concentrations of  Hp in serum, 
but was here adapted to be used for milk, as described by Hyvönen et al. 
(2006). Optical densities of  the formed complex were measured at 450 
nm using a spectrophotometer. Lyophilised bovine acute phase serum 
was used as a standard, and calibration was carried out according to the 
European Union concerted action on standardization of  animal APP 
(number QLK5-CT-1999-0153). The working range of  the assay was 60 
to 1900 mg/l. The inter-assay and intra-assay CV values for Hp analysis 
were <8% and <13%, respectively.
4.4.3.2. Milk N-acetyl-β-D-glucosaminidase (NAGase) activity 
determination (II, IV)
Milk NAGase activity was measured by a fl uoro-optical method using an 
in-house microplate modifi cation developed by Mattila and Sandholm 
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(1986) and further modifi ed by Hovinen et al. (2010) in the laboratory 
of  the Department of  Production Animal Medicine, University of  
Helsinki. The calibrated milk sample was replaced with a control milk 
sample with a known 4-methyl-umbelliferon (4-MU) concentration, and 
NAGase activity was expressed as picomoles of  4-MU/min/μl of  milk 
at 25°C. The upper detection limit for NAGase activity was 24.5 pmol 
4-MU/min/μl. Inter-assay and intra-assay CVs for the NAGase activity 
were 5% and 4%, respectively.
4.4.4. Antimicrobial susceptibility testing (III)
Pure cultures of  clinical mastitis pathogens were tested for antibacterial 
susceptibility with the disc diffusion assay on Mueller–Hinton agar. 
Testing was performed according to the guidelines of  the Clinical and 
Laboratory Standards Institute (CLSI) document M31-A2 in the years 
2007–2008 and M31-A3 in 2009 (CLSI 2002; 2008). Quality control 
strains, S. aureus ATCC® 25923, E. coli ATCC® 25922, Pseudomonas 
aeruginosa ATCC® 27853 and Str. pneumoniae ATCC® 49619, were included 
with each batch of  isolates tested. The antimicrobial susceptibility of  
Gram-positive bacteria was tested with penicillin, ampicillin, cephalothin, 
clindamycin, erythromycin, gentamycin, trimethoprim/sulfa and 
tetracycline. The antimicrobial susceptibility of  Gram-negative bacteria 
was tested with ampicillin, gentamycin, trimethoprim/sulfa, tetracycline, 
enrofl oxacin, streptomycin, neomycin and cefaperazone. The list of  
antibiotics in susceptibility testing may vary, as different veterinarians 
preferred a different set of  antibiotics in order to fi nd the best solution 
for treatment after having received the laboratory test results. The criteria 






















































































































































































































































































































































































































In the study IV, any lactating dairy cow with clinical mastitis was 
considered for enrollment in the trial. Initial exclusion criteria were 
cows with more than one quarter affected and cows with known chronic 
mastitis, defi ned as cows with known high somatic SCC or cows having 
had more than three mastitis episodes before the beginning of  the study. 
All cows with clinical mastitis were allocated into treatment groups A and 
B using cow ID (A: even numbers and B: odd numbers). The following 
two treatments were used: parenteral treatment with benzylpenicillin 
procaine (Penovet® vet 300 mg/mL, Boehringer Ingelheim Vetmedica, 
Denmark) in group A or IMM treatment with benzylpenicillin procaine 
(Carepen® 600 mg, Vetcare Oy, Finland) in group B. One IMM 
tube was infused into the affected quarter once a day. The dose of  
benzylpenicillin used for parenteral treatment was 20 mg (20, 000 IU) 
per kg intramuscularly once a day. The duration of  treatment was 5 days 
in both groups. The use of  supportive treatment with non-steroidal 
anti-infl ammatory agents (NSAID) was possible, but treatment with 
corticosteroids was not allowed. Treatment with penicillin according to 
the defi ned treatment groups began on the day of  diagnosis. Treatment 
was stopped on the next day if  Gram-negative bacteria were detected 
on the selective media or if  the isolated staphylococci were resistant to 
penicillin (a positive nitrocefi n test). Cases of  clinical mastitis caused by 
Gram-negative bacteria (n=41) were treated with NSAID, fl uid therapy 
and if  the case was severe, with fl uoroquinolones. Udder quarters 
infected with penicillin-resistant staphylococci were treated with IMM 
cloxacillin (Wedeclox mastitis® 1,000 mg cloxacillin, WDT, Garbsen, 
Germany) once a day for 5 days.
4.5.1. Assessment of treatment outcome
The outcome of  the treatment was assessed 3-4 weeks after the onset 
of  treatment by using clinical, infl ammatory and bacteriological criteria. 
The milk samples were collected as described above and frozen at -20°C. 
The cow was defi ned as clinically cured if  the affected quarter was free 
from clinical signs. A quarter was defi ned as bacteriologically cured if  the 
DNA of  the same bacterial species detected in the pre-treatment milk 
sample was not present in the follow-up milk sample. A quarter with the 
DNA from the same bacterial species detected before the treatment was 
defi ned as not cured. 
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Milk NAGase activity was determined in the pre-treatment and post-
treatment milk samples, and used as an additional parameter to compare 
outcomes in the treatment groups (Hovinen et al., 2010). 
Composite milk somatic cell counts (CMSCC) from the cows included in 
the study were collected from the study herds once each month during a 
3 month period after the treatment; the mean number of  recordings per 
cow was 2.6. The culling data were analyzed during a six month period 
after the treatment. These data originated from the routine herd health 
recording system.
4.5.2. The fi nal enrollment criteria
Only cows with one affected udder quarter (n=140) with penicillin- 
susceptible Gram-positive bacteria were included into the study based 
on the following criteria regarding the species detected by the PCR 
assay: 1) DNA of  one bacterial species only; or 2) DNA of  one bacterial 
species in proportion over 99% from DNA of  all target bacterial species 
detected 3) >90% DNA of  a major pathogen combined with a low 
quantity (+) of  DNA of  a minor pathogen (CNS or C. bovis). 
PCR-negative samples (n = 25), contaminated samples (more than 
three different species detected) (n = 27), and samples containing DNA 
from Gram-negative bacteria (n = 11) were removed from the study. 
Cows (n=44) treated with IMM cloxacillin, and cows (n = 26) with 
blaZ gene positive staphylococcal species, but treated unintendedly with 
benzylpenicillin were excluded from the main material, but analyzed 
separately.
4.6. Statistical analysis (I-IV)
Stata 9.2 software and Stata 10.0 (StataCorp, Texas, USA) were used for 
statistical analysis in Study I and in Studies II-IV, respectively. Statistical 
signifi cance was assumed at p ≤ 0.005.
In Study I, the logistic regression with a random herd effect for 
controlling clustering was used to analyse the effect of  the housing 
system (free-stall, tie-stall with short stall-length or tie-stall with long 
stall-length) and the time span between moving heifers to the calving 
facility and the day of  calving on the occurrence of  clinical mastitis. 
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To simplify the modelling, the continuous variable, number of  days 
from moving heifers to the calving facility and expected parturition, was 
transformed to a dichotomous variable (≤14 days vs. >14 day- classes) 
in the model. Odds ratios (OR) with a 95% confi dence interval (95% 
CI) were calculated. 
A two-sample proportion test was used to estimate statistical signifi cance 
of  differences in occurrence of  udder pathogens between fi rst-calving 
heifers and multiparous cows. These analyses were conducted using 
statistical software Statistix for Windows 2.0.
In Study II, generalized linear mixed models (GLMM) were used to 
investigate associations between milk APPs and PCR results. Only milk 
samples with PCR negative result or ≤3 pathogen species were analysed 
(n=253). The outcome variable MAA was logarithmically transformed, 
and the inverse square root transformation of  Hp was used. As Hp 
is evaluated using a model in inverse scale, negative model estimates 
represent higher Hp concentrations. The full models included lactation 
number as a 4-level categorical variable (1, 2, 3 and ≥4 lactations), days 
in milk was categorized as a 4-level variable according to quartiles (1-
19, 20-59, 60-118, and 119-412 days in milk), farm as a 3-level variable, 
and affected quarter as a 2-level variable (fore and hind quarters). These 
variables were kept in all models to control possible confounding effects. 
As these variables were not signifi cant in any of  the models (except 
affected quarters in the MAA model), they are not shown in results. PCR 
results by pathogen were included as categorical variables (negative, +; 
++; or +++). If  PCR results were under 6 cases per level, they were 
consolidated with the previous factor level as follows: C. bovis ++ with 
C. bovis +; Str. agalactiae +++ with Str. agalactiae ++; Str. dysgalactiae +++ 
with Str. dysgalactiae ++; T. pyogenes +++ with T. pyogenes ++; and CNS 
+++ with CNS ++. To account for clustering of  data (13 cows had two 
samples from different quarters), cow was included as a random factor.
The Wald test was used to evaluate the overall signifi cance of  the 
categorical variables with more than two levels. Non-signifi cant PCR 
result variables were removed using the stepwise backward elimination 
procedure. Both fi nal models were tested for interactions between minor 
pathogens (C. bovis and CNS) and major pathogens (E. coli, T. pyogenes, 
Str. uberis, and Str. dysgalactiae).
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The random effects Tobit regression model for censored data was used 
to investigate associations between milk NAGase activity and PCR 
results. The Tobit regression model was chosen because >40% of  the 
NAGase results were over the maximum working limit of  the assay 
(24.5 pmol 4-MU/min/μl), which would violate the regression model’s 
assumptions. In the Tobit regression, all cases falling above (or below) 
a specifi ed threshold value are censored, although these cases remain 
in the analysis (Long, 1997). A more detailed explanation using Tobit 
regression for analysing milk NAGase activity data is given by Pyörälä 
et al. (2011). Square root transformation of  milk NAGase activities was 
used to achieve a normal distribution of  uncensored data; 104 samples 
were censored at the level of  24.5 pmol 4-MU/min/μl. All other model 
building strategies and variables in each model were as described for the 
APP models above. 
A linear regression model for APPs and a Tobit regression model for 
NAGase were employed to investigate the association between milk APP 
concentrations and milk NAGase activities with the severity of  clinical 
mastitis (mild, moderate, and severe signs). Assumptions of  all models 
were controlled using normality and scatter plots of  model residuals.
In Study III, the logistic regression model with a random herd effect for 
the control of  clustering was used for all the analyses in this study. OR 
with 95% confi dence intervals (95% CI) were calculated. 
The infl uence of  milk samples with mixed growth or no bacterial 
growth on the occurrence of  clinical or subclinical mastitis was assessed. 
Potential interactions (no growth or mixed growth × year) were assessed 
in the logistic regression model. The effects of  herd size and year on 
the pathogens that caused clinical and subclinical mastitis were analysed. 
Prior to the beginning of  the study IV, the sample size necessary for 
statistical evaluation was calculated as 106 in both treatment groups. The 
calculations were based on the hypothesis that differences in the cure rates 
of  the parenteral vs. IMM treatment are less than 20% (bacteriological 
cure rates of  65% and 45%, respectively; two-sided p-level at 0.05 and a 
study power of  80%). This hypothesis was based on the assumption that 
a large proportion of  cases would be caused by S. aureus. However, after 
collection of  the data a large proportion of  the cows were lost, due to 
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missing data or reasons for post-inclusion exclusions and the power of  
the study to detect at least a 20% difference in the bacteriological cure 
was 59% (sample size of  61 in the parenteral group and 79 in the IMM 
group).
Logistic regression models were used to evaluate the associations between 
clinical and bacteriological cures, with treatment route. Bacteriological 
and clinical cures were the outcome variables. The treatment route (IMM, 
parenteral), bacteriological diagnosis as a 7-level categorical variable (S. 
aureus, CNS, Str. agalactiae, Str. dysgalactiae, Str. uberis, C. bovis, T. pyogenes), 
and a continuous variable milk NAGase activity in the pre-treatment 
milk samples (as a marker of  the severity of  the infl ammation) were 
included as independent variables. Additionally, the lactation number 
was used as a 4-level categorical variable (1, 2, 3 and ≥ 4 lactations), 
the days in milk was used as a 4-level categorized variable (1-30, 31-
69, 70-140 and > 140 days in milk), and the farm and affected quarter 
were used as a 4-level variable. Non-signifi cant variables were removed 
using a stepwise backward elimination procedure. The Wald test was 
used to evaluate the overall signifi cance of  the categorical variables with 
more than two levels. No signifi cant interactions were detected and as 
no included variables were associated with any outcome variables both 
fi nal models included only treatment route as independent variable.
Differences in the number of  culled cows between the treatment groups 
during the 6 months after treatment were analyzed with logistic model 
in which the treatment, farm, days in milk and lactation number were 
included. Variables were categorized similarly to the previous models.
A linear regression model was used to investigate the associations 
between milk NAGase activity in the post-treatment milk samples 
and the route of  treatment. Before analysis, the outcome variable milk 
NAGase activity was logarithmically transformed. The full models 
included bacteriological recovery (yes/no), clinical recovery (yes/no), 
treatment route, diagnosed pathogens and milk NAGase activity in 
clinical mastitis in the pre-treatment milk samples, lactation number, 
days in milk, farm and affected quarter as fi xed variables. The variables 
categorized similarly to the previous logistic regression models. The 
Wald test was used to evaluate the overall signifi cance of  the categorical 
variables with more than two levels. Non-signifi cant variables were 
removed using a stepwise backward elimination procedure. Possible 
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interaction effects of  the treatment with diagnosed clinical mastitis 
pathogens, bacteriological cure, clinical cure and farm were verifi ed. No 
signifi cant interactions were detected. Assumptions of  the model were 
controlled using normality and scatter plots of  the model residuals. Stata 
11.0 (Stata Corp, Texas, USA) software was used for logistic regression 
models and linear regression model.
For analyzing associations between the treatment and low CMSCC 
(<200,000 cells/ml) occurrence during the 21-110 days after the mastitis 
cases, generalized linear mixed model was used. For this model, the 
GLIMMIX procedure in the SAS/STAT 9.1 software (SAS Institute 
Inc., Cary, NC, USA) was used. An auto-regressive correlation structure 
was used for modeling serial correlations of  repeated measurements 
within cows. Treatment, time group after mastitis (21-50, 51-80 and 81-
110 days) and their interaction, sample time in relation to mastitis, days 
in milk at the time of  mastitis, and farm were included as fi xed factors. 
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5. RESULTS
5.1. Risk factors for clinical mastitis in primiparous cows at 
calving (I)
Approximately 40% (423) of  the fi rst-calving heifers were housed on tie-
stall farms and approximately 60% (640) were kept on free-stall farms. 
The overall occurrence of  clinical mastitis at calving of  the heifers was 
6.4% (n = 68), being 9.7% (n = 41) on tie-stall farms compared with 4.1 
% (n = 27) on free-stall farms. 
Housing system was not a signifi cant risk factor for clinical mastitis 
of  freshly calved heifers (Table 4). The number of  days from moving 
heifers to the calving facility and expected parturition was from 0 to76, 
whereas the average number of  days was 26. On tie-stall farms, the 
heifers moved to the calving facility less than two weeks prior to the 
expected date of  parturition had a higher risk (OR = 5.9; p = 0.001) to 
































































































































































































































































































































































































































































The most common udder pathogens in both housing systems were Str. 
uberis, E. coli and CNS (Figure 1). Occurrence of E. coli mastitis was 
higher in free-stall farms compared to tie-stall farms, while Str. uberis was 
more frequent on tie-stall farms. The differences were not statistically 
































































































Figure 1. Distribution of  udder pathogens in freshly calved heifers in two housing 
systems (I).
*calculated against the total number of  isolates from heifers from both housing systems
5.2. Udder pathogens isolated from clinical and subclinical 
mastitis in Estonia 
5.2.1. Clinical mastitis pathogens in primiparous and 
multiparous dairy cows at calving (I)
In total, 303 cases of  clinical mastitis were identifi ed in 2355 multiparous 
cows (12.8%) on the day of  parturition. Udder pathogens were isolated 
from 49 (72%) out of  68 cases of  clinical mastitis in freshly calved 
heifers and from 185 (61%) out of  303 cases in multiparous cows. 
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The most frequently isolated bacteria from milk samples of  freshly 
calved heifers were E. coli and Str. uberis. No clinical mastitis caused by 
Str. agalactiae or Corynebacterium spp. was discovered, and only one case 
of  S. aureus mastitis was found in heifers. In contrast, S. aureus was the 
most common bacterium isolated from the milk of  affected multiparous 
cows, followed by Str. uberis, and E. coli. Differences between heifers 
and cows regarding the occurrence of  clinical mastitis were statistically 
signifi cant for Str. uberis (p = 0.037), coliforms (p = 0.002), and S. aureus 
(p = 0.019). Bacteriological fi ndings are presented in Table 5. 
Table 5. Bacterial species isolated from milk samples of  heifers and multiparous cows 
having clinical mastitis at parturition.
Heifers Cows 
Pathogens % n % n
E. coli 1 22.1 15 6.6 20
Str. uberis 1 19.1 13 9.9 30
CNS 8.8 6 7.3 22
Lactococcus lactis 4.4 3 5.0 15
Klebsiella spp. 4.4 3 2.3 7
Str. spp. 2.9 2 3 9
Enterococcus spp. 2.9 2 2.3 7
Pseudomonas spp. 2.9 2 0.7 2
S. aureus 1 1.5 1 11.2 34
Arcanobacterium spp. 1.5 1 2.6 8
Str. dysgalactiae 1.5 1 3.6 11
Corynebacterium spp. 0 0 2.0 6
Str. agalactiae 0 0 3.3 10
Candida spp. 0 0 1.3 4
No growth 25 17 29.4 89
Mixed culture 2.9 2 9.6 29
Total 100 68 100 303
1 The difference between heifers and multiparous cows is statistically signifi cant (p < 
0.005)
5.2.2. Isolation of mastitis pathogens from milk samples 
submitted to the Veterinary and Food Laboratory in 2007-2009 
(III)
Over the three-year period, 3058 clinical mastitis samples from 190 farms 
and 5146 subclinical mastitis samples from 274 farms were investigated. 
Positive results were found in 57% of  the samples (4680 out of  8204), 
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and this proportion did not change over the three years (p > 0.05). The 
proportion of  bacteriologically negative samples was 22.3% and that of  
mixed growth 20.6%. There was a signifi cantly higher chance (OR = 
1.15, 95% CI = 1.01, 1.33, p = 0.042) of  fi nding bacteriologically negative 
samples in the presence of  subclinical mastitis (n = 1,317; 25.6%) in 
comparison with clinical mastitis (n = 554; 16.8%). The probability of  
obtaining mixed growth from milk samples was also signifi cantly higher 
(OR = 2.2, 95% CI = 1.9, 2.6, p < 0.001) in case subclinical mastitis was 
found. The distribution of  bacterial species isolated from milk samples 
of  cows with clinical and subclinical mastitis is shown in Table 6.
Table 6. Distribution of  bacterial species isolated from clinical and subclinical mastitis 
samples in 2007–2009.













S. aureus 11.7 11.7 11.7 19.2 22.8 16.6
CNS 4.8 7.1 8.5 16.1 13.6 17.4
CPS1 3.8 3.3 1.6 4.6 2.8 5.1
Str. agalactiae 9.0 11.3 14.7 13.6 9.0 10.7
Str. dysgalactiae 8.0 7.8 7.2 3.6 4.0 5.6
Str. uberis 16.1 21.8 17.1 10.2 12.3 12.9
Str. spp 3.2 3.3 1.9 1.2 2.0 2.7
Lactococcus 
lactis
10.9 3.9 5.7 8.9 8.2 3.9
E. coli 14.4 16.6 16.5 1.6 2.0 3.8
Klebsiella spp. 7.0 1.3 2.3 0.7 0.6 0.9
Enterococcus 
spp.
1.3 2.3 1.1 1.5 2.8 4.2
Corynebacterium 
spp.
2.2 2.6 5.0 16.5 17.3 8.5
T. pyogenes 2.2 3.8 3.6 0.1 0.6 0.6
Pseudomonas 
spp.
1 0.3 0.3 0 0 0.6
Proteus spp. 0.2 0 0.2 0.4 0.1 0.6
Yeast 2.3 2 1.6 1.5 1.6 5.6
Other 1.8 0.9 1 0.3 0.3 0.3
Total 100% 100% 100% 100% 100% 100%
1 Coagulase-positive staphylococci
Among the bacteriologically positive (n = 2016) clinical mastitis samples, 
Str. uberis was the bacterium isolated most frequently (n = 371; 18.4% 
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of  the positive samples), followed by E. coli (n = 321; 15.9%), and Str. 
agalactiae (n = 293; 11.9%). S. aureus (n = 532; 20%) and CNS (n = 411; 
15.4%) were the bacteria isolated most commonly from milk in cases of  
subclinical mastitis, followed by Corynebacterium spp. (n = 395; 14.8%). 
The probability of  isolating S. aureus from milk samples was signifi cantly 
higher on farms having fewer than 30 cows, compared with the farms 
with more than 100 cows (OR = 0.2, 95% CI = 0.11, 0.53, p < 0.005). 
Also, there was a signifi cantly higher risk of  diagnosing Str. agalactiae on 
farms with more than 600 cows (OR = 17.6, 95% CI = 1.2, 259.1, p = 
0.034), compared with smaller farms. 
5.2.3. Bacteriological fi ndings using PCR-based analysis (II)
PCR-based mastitis diagnostics was used and ten different species of  
udder pathogens were detected in 281 quarter milk samples from cows 
with clinical mastitis. A total of  27 milk samples (9.6%) were PCR-
negative, and 254 (90.4%) samples contained DNA from at least one 
target species. Milk samples containing DNA from four or more bacterial 
species (n = 28) were considered possibly contaminated and excluded 
from further analysis. In total, 443 bacterial identifi cations were made 
from the remaining 226 milk samples. A single bacterial species was 
found in 68 (30.1%), 2 species were found in 99 (40.8%), and 3 species 
were found in 59 (26.1%) of  the DNA-positive milk samples.
The most prevalent bacterial species in the milk samples containing 
a single pathogen were Str. uberis (n = 20; 29.4%), S. aureus (n = 14; 
20.5%), and E. coli (n = 13; 19.1%). Str. uberis was detected in 45 (45.4%) 
and CNS in 40 (40.4%) of  the milk samples with two bacterial species. 
Different bacterial DNA quantities and proportions of  mastitis-causing 
bacteria were detected in the milk samples (Table 7.).
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Table 7. Bacterial DNA quantities of  udder pathogens detected in 226 milk samples 
from cases of  naturally occurring clinical mastitis. 
n (%) mean Ct-values2
Identifi ed mastitis
pathogens (n = 443)
% of all DNA-
positive milk
samples (n = 226)
+1 ++ +++ 









































Enterococcus spp. (n = 4) 1.7% 4 (100)
35.6
0 0






Klebsiella spp. (n = 2) 0.9% 2 (100)
32.5
0 0
1 + - low quantities of  bacterial DNA (range of  Ct-values 28.3-37)
  ++ - intermediate quantities of  bacterial DNA (range of  Ct-values 22.1-33.7)
  +++ - high quantities of  bacterial DNA (range of  Ct-values 13.4-27.4)
2Ct-values of  each pathogen based on quantity of  bacterial DNA 
None of  the milk samples contained two or three bacterial species in 
high quantities simultaneously. The quantity was low (+) in 78 (85.7%) 
out of  the 98 milk samples containing DNA from CNS. Bacterial DNA 
from Enterococcus spp. and Klebsiella spp. was detected rarely and only in 
low quantities.
5.3. The local infl ammatory response in clinical mastitis (II)
5.3.1. Associations between the severity of clinical mastitis and 
acute phase proteins
An association between the severity of  clinical signs and the concentrations 
of  APP and NAGase activity in the milk was found. In cases of  severe 
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clinical mastitis, MAA, Hp and NAGase activity values were signifi cantly 
higher, compared with cases of  clinical mastitis with mild or moderate 
signs (p < 0.001, p = 0.006, and p = 0.021, respectively). Concentrations 
of  MAA and Hp and NAGase activity in milk from cows with moderate 
clinical mastitis were signifi cantly higher than the values measured in 
milk from cows with mild clinical signs (p < 0.001, p = 0.007, and p < 
0.001, respectively).
5.3.2. Udder pathogens of clinical mastitis and the concentration 
of APP and NAGase activity
The concentration of  MAA in milk ranged between 0.94 and 1500 
mg/l (median 43.3 mg/l, IQR 16.9-183.3 mg/l), and Hp varied from 
59 mg/l to 1890 mg/l (median 214.1 mg/l, IQR 105.7-398.6). Two our 
of  253 milk samples had an MAA concentration below the working 
limits of  the assay, while in 13 samples it was above the working limits 
of  the assay (0.94 and 1500 mg/l, respectively). Twenty one samples 
had Hp concentrations under the working limit of  the assay (59 mg/l). 
The activity of  NAGase in milk ranged between 0.53 and 24.5 pmol 
4-MU/min/μl (median 19.5 pmol 4-MU/min/μl, IQR 7.9-24.5 pmol 
4-MU/min/μl), and in 104 milk samples the NAGase activity was 
above the working range of  the assay (24.5 pmol 4-MU/min/μl). The 
median concentrations of  APP and NAGase activity in different udder 
pathogens are presented in Table 8.
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Table 8. Concentrations of  milk amyloid A (MAA), haptoglobin (Hp) and N-acetyl-β-










35.8 (6.7; 1500) 201.1 (59.0; 756.2) 22.5 (2.7; 24.5)
CNS
(n = 11)
29.2 (8.5; 1500) 123 (59.0; 775.5) 11.86 (6.6; 24.5)
Str. agalactiae
(n = 4)
53.5 (28.9; 735.7) 295.5 (172.1; 506.1) 20.6 (6.6; 24.5)
Str. dysgalactiae
(n = 19)
147.6 (7.2; 905.2) 248.9 (74.8; 1118.2) 20.8 (3.28; 24.5)
Str. uberis
(n = 36)
53.1 (4.5; 1500) 385.6 (59.0; 970.3) 24.5 (3.36; 24.5)
T. pyogenes
(n = 10)
25.6 (0.95; 348.9) 618.5 (5.0; 1155.8) 24.5 (1.73; 24.5)
C. bovis
(n = 4)
12.4 (0.09; 107.3) 95.8 (59.0; 108.6) 9.9 (0.5; 14.7)
E. coli
(n = 18)
394.1 (1.75; 1500) 575.4 (59.0; 1288.1) 24.5 (2.5; 24.5)
PCR-negative
(n = 27)
23.2 (7.4; 152.2) 164.1 (59.0; 548.3) 9.2 (1.3; 24.5)
1 Only milk samples containing 1 bacterial species only or 1 bacterial species in large quantity 
(+++) are included in the table.
Concentrations of  Hp and MAA and NAGase activity in the milk were 
not affected by farm, lactation number, or days in milk (p > 0.05). The 
affected quarter (fore or hind) did not affect the Hp concentrations or 
the NAGase activities in milk (p > 0.05; data not shown). Hp and MAA 
concentrations and NAGase activity in the milk were signifi cantly higher 
when E. coli ++ and +++ or Str. dysgalactiae ++/+++ were detected, 
compared with all other milk samples where these species were not 
detected. 
Furthermore, a low quantity (+) of  E. coli in milk samples was associated 
with an elevated NAGase activity and MAA concentration (Tables 9, 10 
and 11). The presence of  T. pyogenes at high levels in milk samples caused 
a signifi cant elevation of  Hp, as well as an increased NAGase activity in 
the milk (p < 0.001; p < 0.001), compared with milk samples without 
T. pyogenes. However, no association between the MAA concentration 
and the presence of  T. pyogenes was found (p > 0.05; data not shown). 
Milk samples containing DNA from C. bovis or a low quantity of  DNA 
from CNS had a signifi cantly lower concentration of  APP and a lower 
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NAGase activity, compared with all other milk samples where other 
species were detected. 
No interaction was detected in the models between minor (C. bovis 
and CNS) and major (E. coli, Str. dysgalactiae, T. pyogenes, and Str. uberis) 
pathogens. This means that none of  the associations between the major 
pathogen DNA and the concentrations of  the infl ammatory markers 
were infl uenced by the presence of  the minor pathogen DNA in the 
milk samples.
Table 9. Final generalized linear mixed model (GLMM) of  associations between the 
concentration of  milk amyloid A (MAA) in the milk and the pathogens detected with 
PCR (n = 253) from naturally occurring clinical mastitis.
Variable1 Estimate2 95% CI p-value Wald test 
p-value
Quarters
  fore quarters (n = 102)
  hind quarters (n = 179)
E. coli
  E. coli negative3 (n = 186)
  +c (n = 19)
  ++ (n = 30)
  +++ (n = 18)
Str. dysgalactiae
  Str. dysgalactiae negative (n = 220)
  + (n = 14)
  ++/+++ (n = 19)
C. bovis
  C. bovis negative (n = 200)
































1 + - low quantities of  bacterial DNA 
  ++ - intermediate quantities of  bacterial DNA 
  +++ - high quantities of  bacterial DNA
2 Estimates are on the logarithmic scale 
3 Number of  milk samples not containing DNA from detected bacteria
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Table 10. Final generalized linear mixed model (GLMM) of  associations between 
concentration of  haptoglobin (Hp) in the milk and the pathogens detected with PCR 
(n = 253) from naturally occurring clinical mastitis.
Variable1 Estimate2 95% CI p-value Wald test 
p-value
T. pyogenes
  T. pyogenes negative3 (n = 219)
  + (n = 24)
  ++/+++ (n = 10)
E. coli
  E. coli negative (n = 186)
  + (n = 19)
  ++ (n = 30)
  +++ (n = 18)
Str. uberis
  Str. uberis negative (n = 164)
  + (n = 33)
  ++ (n = 29)
  +++ (n = 36)
Str. dysgalactiae
  Str. dysgalactiae negative (n = 220)
  + (n = 14)
  ++/+++ (n = 19)
CNS
  CNS negative( n = 162)
  + (n = 78)
  ++/+++ (n = 13)
C. bovis
  C. bovis negative (n = 200)























































1 + - low quantities of  bacterial DNA 
  ++ - intermediate quantities of  bacterial DNA 
  +++ - high quantities of  bacterial DNA
2 Estimates are on the inverse square root scale (negative estimate means higher 
concentration of  Hp)
3 Number of  milk samples not containing DNA from detected bacteria
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Table 11. Random effects Tobit regression model of  associations between N-acetyl-
β-D-glucosaminidase (NAGase) activity in the milk and the pathogens detected with 
PCR (n = 253) from naturally occurring clinical mastitis.
Variable1 Estimate2 95% CI p-value Wald test 
p-value
T. pyogenes
  T. pyogenes negative3 (n = 219)
  + (n = 24)
  ++/+++(n = 10)
E. coli
  E. coli negative (n = 186)
  + (n = 19)
  ++ (n = 30)
  +++ (n = 18)
Str. uberis
  Str. uberis negative (n = 164)
  + (n = 18)
  ++ (n = 17)
  +++ (n = 30)
Str. dysgalactiae
  Str. dysgalactiae negative (n = 220)
  + (n = 14)
  ++/+++ (n = 19)
CNS
  CNS negative (n = 162)
  + (n = 78)
  ++/+++ (n = 13)
C. bovis
  C. bovis negative (n = 200)
  +/++ (n = 53)
PCR-positive (n = 226)



























































1 + - low quantities of bacterial DNA 
  ++ - intermediate quantities of bacterial DNA 
  +++ - high quantities of bacterial DNA
2 Estimates are shown on a square root scale
3 Number of milk samples not containing DNA from detected bacteria
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5.4. Treatment effi cacy of  clinical mastitis of  Gram-positive 
mastitis pathogens using penicillin G (IV)
5.4.1. Outcome of benzylpenicillin treatment
In total, 140 quarters with clinical mastitis were included in the study. 
Clinical signs were defi ned as mild in 83 cows (59.2%) and moderate 
in 55 cows (39.2%). Mastitis was defi ned as severe in two cows (1.4%). 
Of  140 quarter cases with clinical mastitis, 61 (43.6%) were treated 
with benzylpenicillin via the parenteral route and 79 (56.4%) with 
benzylpenicillin via the IMM route Distribution of  the bacteria detected 
in the milk samples did not signifi cantly differ between the treatment 
groups (Table 1). Str. uberis was the most common bacteriological fi nding, 
followed by other streptococcal species. No signifi cant associations 
between the clinical cure (OR = 1.38; 95% CI 0.62, 3.12; p= 0.431) or 
bacteriological cure (OR = 0.94; 95% CI 0.48, 1.83; p= 0.851) and the 
route of  treatment were observed. The cure rates for the 140 quarters 
with clinical mastitis infected by Gram-positive bacteria susceptible to 
benzylpenicillin in vitro are shown in Table 12.
Table 12. The outcome of  parenteral and intramammary 5-day treatment with 
benzylpenicillin of  bovine clinical mastitis (n = 140 quarters) caused by Gram-positive 
bacteria susceptible to benzylpenicillin in vitro.
Pathogen Clinical cure Bacteriological cure
IM1 n IMM2 n IM1 n IMM2 n
S. aureus (n = 8) 1/2 5/6 1/2 5/6
CNS (n = 13) 4/6 6/7 2/6 4/7
Str. uberis (n = 66) 29/34 22/32 20/34 16/32
Str. agalactiae (n = 14) 6/6 6/8 4/6 6/8
Str. dysgalactiae (n = 19) 5/8 9/11 5/8 8/11
C. bovis (n = 6) 1/1 3/5 0/1 3/5
T. pyogenes / P.indolicus 
(n = 14) 3/4 8/10 1/4 2/10
Total (n = 139) 
(%)3




1 Intramuscular (parenteral) treatment
2 Intramammary treatment 
3 The propotion of  cured udder quarters
Milk NAGase activities in the post-treatment samples did not differ 
between the two treatment groups (p= 0.688; Table 13). Milk NAGase 
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activity was signifi cantly lower (p = 0.003) in the quarters with a clinical 
cure than the quarters with no clinical cure and in the bacteriologically 
cured quarters compared with those without bacteriological cure (p = 
0.002; Table 13)
Table 13. Linear regression model of  associations between milk NAGase activity in 
the post- treatment milk sample (n = 140) and route (intramammary or parenteral) of  
treatment in clinical mastitis caused by Gram-positive bacteria.
Variable Estimate1 95% CI p-value Wald test 
p-value
Treatment 
   IMM (n = 79)
   IM (n = 61)
Bacteriological cure
   No (n =63)
   Yes (n = 77)
Clinical cure
   No (n = 32)
   Yes (n = 108)
Farm
   Farm 1. (n = 17)
   Farm 2. (n = 11)
   Farm 3. (n = 66)




























1 Estimates are in logarithmic scale
The median NAGase activities in the milk before treatment and in the 
post-treatment samples are presented in Table 14. 
Table 14. Milk NAGase activity in milk samples from quarters with clinical or 
bacteriological cure or no cure (n = 140) before and after 5-day parenteral or 
intramammary penicillin treatment of  clinical mastitis caused by Gram-positive 
bacteria.
Median milk NAGase activity (min; max)
(pmol 4-MU/min/μl
Before treatment After treatment
Clinical cure 
  Yes (n = 108)






  Yes (n = 77)






  IM (n = 61)






In total, the number of  culled cows was 18 (13.1%) by the end of  the 
6 month follow-up period after treatment. No data were available for 3 
cows. No signifi cant differences between the treatment groups (OR = 
0.91, 95% 0.33, 2.46, p = 0.507) were found. 
5.4.2. Composite milk somatic cell count after treatment
Individual cow CMSCC data from three test milkings during the 3-month 
follow-up period after treatment (21-110 days) were available for 126 
cows. The summary of  data and the proportion of  cows with CMSCCs 
less than 200,000 cells/ml in the two treatment groups at different time 
points after treatment is shown in table 15. No association (p= 0.787) 
between the route of  penicillin treatment and the proportion of  cows 
with CMSCC <200,000/ml was seen.
Table 15. Individual cow composite milk somatic cell counts (CMSCCs) and 
proportions of  cows with CMSCCs <200,000 cells/mL collected during a 3-month 
period (21-110 days) after parenteral or intramammary penicillin treatment of  clinical 















  IM1 (n = 59)













  IM1 (n = 49)













  IM1 (n = 46)












1 Intramuscular (parenteral) treatment
2 Intramammary treatment
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5.5. Antimicrobial resistance of  clinical mastitis pathogens (III)
The proportion of  S. aureus isolates resistant to penicillin and ampicillin 
accounted for 61.4% and 59.5%, respectively. In addition, CNS showed 
resistance to penicillin and ampicillin (38.5% and 34.4%, respectively), 
while resistance to erythromycin and lincomycin was also common 
(14.9% and 17.6%, respectively). Six isolates (3.8%) of  S. aureus and three 
isolates (3.6%) of  CNS were resistant to cephalothin. All streptococci 
(Table 16) were susceptible to penicillin, ampicillin and cephalothin, 
except for one isolate of  Str. uberis. Of  the 90 isolates of Str. dysgalactiae, 
32.2% were classifi ed as resistant to tetracycline. Of  the 151 isolates of 
Str. uberis 14.3% isolates resistant to tetracycline were recorded. 
Table 16. Antimicrobial resistance of  staphylococci and streptococci isolated from 
bovine clinical mastitis cases. 

















Ampicillin 10 173 59.5 91 38.5 162 0 111 0 265 0.4
Penicillin 10 174 61.4 93 34.4 168 0 111 0 267 0.4
Cephalothin 30 160 3.8 84 3.6 143 0 101 0 254 0.4
Clindamycin 2 169 18.1 91 17.6 161 6.2 115 7.8 273 6.6
Erythromycin 15 83 4.8 47 14.9 77 1.3 60 6.7 134 8.2
Tetracycline 30 147 4.1 86 11.6 151 14.6 90 32.2 234 19.7
Trimethoprim
/sulfa 1.25/23.75 162 3.4 76 2.6 140 6.4 103 1 223 3.2
Gentamycin 10 146 6.8 69 1.4 143 24.5 88 11.4 210 18.6
1 Proportion of  resistant (R) isolates.
Among the E. coli isolates (Table 17), the highest percentage showing 
intermediate susceptibility and resistance was observed for ampicillin, 
neomycin, streptomycin, and tetracycline. E. coli was 98.4 % susceptible 
to enrofl oxacin and 100% to cefaperazone.
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Table 17. Antimicrobial resistance of  E. coli and Klebsiella spp. isolated from bovine 
clinical mastitis cases.















Ampicillin 10 201 68.7 7.0 24.3 39 15.4 7.7 76.9
Cefaperazone 75 137 100 0 0 32 100 0 0
Tetracycline 30 184 77.8 8.7 13.5 39 79.6 10.2 10.2
Trimethoprim
/sulfa 1.25/23.75 191 84.3 3.7 12.0 40 97.5 0 2.5
Gentamycin 10 161 94.3 2.5 2.2 40 95.0 0 5.0
Streptomycin 30 154 78.6 5.8 15.6 37 73.0 8.1 18.9
Neomycin 30 155 72.9 20.6 6.5 37 83.8 13.5 2.7
Enrofl oxacin 5 185 98.4 0 1.6 37 100 0 0
1 Propotion of  susceptible (S), intermediate (I) and resistant (R) isolates.
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6. DISCUSSION
6.1. Risk factors for clinical mastitis in heifers at parturition (I)
The clinical mastitis incidence rate in our study population of  freshly 
calved heifers was quite modest (6.4%). In 11 large herds using the 
traditional Estonian dairy management system, the occurrence of  clinical 
mastitis of  fi rst-calving heifers did not differ signifi cantly between the 
two housing systems. However, as the number of  herds in this study was 
limited and sample sizes were small in some herds, the results should be 
interpreted with caution. 
In some trials, a higher incidence of  clinical mastitis has been found 
in tie-stall compared to free-stall housing (Ekesbo, 1966; Bakken et al., 
1988; Matzke et al., 1992). The incidence of  clinical mastitis decreased 
over an 18-month period after the management system was changed 
from the tie-stall to the free-stall system (Hultgren, 2002). On tie-stall 
farms the main risk factors for clinical mastitis are teat injuries, short 
stalls, and shortage of  bedding material (Koskiniemi, 1982; Bendixen et 
al., 1988), especially during the periparturient period (Elbers et al., 1997). 
Also, in the tie-stall systems, a higher frequency of  lying down and rising 
may increase the risk of  teat tramping, leading to an increased incidence 
of  clinical mastitis (Oltenacu et al., 1990). In contrast, in loose-housing 
systems cows have suffi cient space for lying down and standing up in a 
more natural way during parturition. At the same time, poor hygiene in 
calving areas is associated with a new IMI around calving and an increased 
clinical mastitis rate (Barellie et al., 2007; Green et al., 2007). Mucking out 
the calving area less often than once a month is a signifi cant risk factor 
for clinical mastitis (Peeler et al., 2000). We found an association between 
the time of  moving close-to-term heifers to the milking farm, and the 
occurrence of  clinical mastitis on tie-stall farms. It has been shown 
that moving heifers to a confi ned area on the day of  calving instead 
of  doing it earlier, moving heifers out from the calving pen too late, or 
milking heifers in the calving pens, leads to an increased incidence of  
clinical mastitis (Svensson et al., 2006; Nyman et al., 2009). Stress and 
sudden changes in environmental and management conditions during 
the periparturient period may weaken natural defense mechanisms in 
animals, making them more susceptible to clinical mastitis.
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6.2. Clinical mastitis pathogens in primiparous and multiparous 
dairy cows at calving (I)
Comparing tie-stall and free-stall farms, the bacterial fi ndings on the 
day of  parturition were generally the same. Mainly bacteria present in 
the surrounding environment were isolated in cases of  clinical mastitis 
of  the freshly calved heifers. These results agree fairly well with those 
from similar studies, reported by other researchers, in which the 
bacteria commonly isolated after parturition were CNS, coliforms and 
streptococci (Gröhn et al., 2004; Tenhagen et al., 2009). In Danish and 
Swedish studies, the most frequently isolated organism was also S. aureus 
followed by Str. dysgalactiae and E. coli (Waage et al., 1998; Persson Waller 
et al., 2009). Our investigation did not show clinical S. aureus mastitis in 
freshly calved heifers, although S. aureus was the predominant pathogen 
in multiparous cows. Predisposing factors for mastitis around calving are 
likely to be similar in heifers and older cows, where the primary source 
of  infection is bovine feces and where the secondary multiplication of  
bacteria to high numbers in bedding and manure is often a risk factor 
(McCarthy and Sears, 2003). 
6.3. Distribution of  udder pathogens in Estonia in 2007-2009 (III)
The distribution of  subclinical and clinical mastitis pathogens was 
analysed in the study based on the analysis of  milk samples submitted 
to the Estonian Veterinary and Food Laboratory over a three-year 
period. The laboratory protocols remained unchanged during the study 
period. In total, 22.3% of  the samples investigated were bacteriologically 
negative. Several other studies have also demonstrated bacteriologically 
negative fi ndings in 17.7 to 26.5% cases of  clinical mastitis, and as many 
as in 28.7 to 38.6% cases of  subclinical mastitis (Sargeant et al., 1998; 
Bradley et al., 2007; Roesch et al., 2007), which are in line with our results. 
The possible reasons for bacteriologically negative fi ndings in milk 
samples might be the presence of  antibacterial substances in the milk 
that lead to a decrease in the viability of  bacteria in the culture (Rainard 
and Riollet, 2006), or failures in the conventional culture compared with 
identifi cation of  bacteria using PCR-test (Taponen et al., 2008).
E. coli and Str. uberis were the pathogens most frequently isolated from 
the milk samples of  the cows with clinical mastitis, while S. aureus, CNS 
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and Corynebacterium spp. were mostly associated with subclinical mastitis. 
Similar results were obtained in a study carried out in Estonia ten years 
ago, where C. bovis (47.5%), S. aureus (21%) and CNS (15.8%) were the 
pathogens isolated most commonly from subclinical cases of  mastitis 
(Haltia et al., 2006). The proportion of  Str. agalactiae positive milk samples 
was surprisingly high in our study. We found a strong association between 
the isolation of  Str. agalactiae and large-scale farms. According to the 
data provided by the Estonian Animal Recording Centre, the number 
of  dairy cows was approximately 98000 and the mean herd size was 
88 cows in Estonia in 2009. Rapid changes in the management system 
(from tie-stall to free-stall) during the last eight years may explain the 
coexistence of  environmental pathogens with Str. agalactiae. Although 
teat disinfection and dry cow therapy are routine mastitis control 
measures used on Estonian dairy farms, proper eradication programmes 
for Str. agalactiae have not been implemented. In contrast, an increased 
probability of  fi nding S. aureus was correlated with farms with fewer 
than 30 cows. The average age of  cows on small farms was 5.3 years 
vs. 4.3 years on farms with more than 300 cows (EARC, 2009). The 
culling policy may be different, and the owners of  smaller farms may 
keep (possibly chronically infected) cows in the herd for a longer period 
of  time.
6.4. A local acute phase response in clinical mastitis diagnosed 
using a quantitative PCR test (II)
The amount of  bacterial DNA detected in the samples from 
cases of  mastitis by certain species was associated with MAA and 
Hp concentrations and NAGase activity in the milk. The highest 
concentrations of  MAA and the highest NAGase activities in the milk 
were found in cows with large quantities of  E. coli in their milk. This is 
in accordance with experimental studies showing a strong infl ammatory 
response to E. coli (Hyvönen et al., 2006; Suojala et al., 2008). Wenz et al. 
(2010) found that the concentration of  Hp was the highest in E. coli-
induced mastitis, compared with the mastitis caused by environmental 
streptococci or CNS. However, even low quantities of  E. coli resulted in 
elevated concentrations of  MAA and an increased NAGase activity in 
the milk. Experimental studies have revealed that even a small quantity 
of  E. coli can induce an acute infl ammatory reaction in the udder (Frost 
et al., 1982). E. coli bacteria are generally rapidly eliminated from the 
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udder, but trigger a strong infl ammatory reaction which is mainly due to 
endotoxin (Burvenich et al., 2003). In practice, the time of  sampling after 
the onset of  clinical mastitis could also infl uence the quantity of  DNA 
of  E. coli in the milk. Delayed sampling during the course of  infection 
could explain the low quantity of  E. coli detected in bacteriological 
examination, despite a strong infl ammatory response. 
Our fi ndings support the results reported by Pyörälä et al. (2011), who 
found that higher concentrations of  Hp and NAGase corresponded to 
the detection of  T. pyogenes in mastitic milk samples but could establish 
no association between T. pyogenes and MAA. This may indicate that 
intramammary infection due to T. pyogenes does not induce signifi cant 
local production of  MAA. Release of  different acute phase proteins 
may depend on the pathogens present. The major producers of  Hp 
and NAGase in the milk are neutrophils and epithelial cells, whereas 
only mammary gland epithelial cells appear to secrete MAA in cows 
with mastitis (Kitchen et al., 1984; Eckersall et al., 2006; Lai et al., 2009). 
Epithelial damage may manifest differently in different infections which, 
in turn, could affect MAA concentrations in the milk.
The presence of  S. aureus in the udder increased the concentrations 
of  APP and the NAGase activity in the milk less than other major 
pathogens, indicating a mild infl ammatory response in this infection. 
In experimentally induced S. aureus mastitis, the concentrations of  Hp 
and MAA ranged between 52 and 323 mg/dl and between 34 and 286 
mg/dl, respectively (Grönlund et al., 2003), and were lower than those 
found in experimentally induced Str. uberis or E. coli mastitis (Pedersen 
et al., 2003; Suojala et al., 2008). The concentrations of  Hp and MAA 
and NAGase activity in naturally acquired S. aureus mastitis were also 
lower than in streptococcal or E. coli mastitis (Pyörälä et al., 2011). In 
the current study, mastitis caused by S. aureus may have been very mild, 
which could explain the weak infl ammatory response detected in the 
udder quarters. A low quantity of  S. aureus DNA in the milk samples 
could also indicate that the bacteria were just skin contaminants and not 
the actual cause of  mastitis (Haveri et al., 2008). 
In our study, CNS and C. bovis were common bacterial species detected, 
mainly in low quantities, in milk samples positive for several species. 
C. bovis and CNS were the main pathogens detected using PCR from 
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milk samples without growth (Taponen et al., 2009) and in the study 
by Koskinen et al. (2010) comparing conventional bacterial culturing 
and PCR in mastitis milk diagnostics. The frequent detection of  these 
bacteria may be due to their extramammary origin. C. bovis and CNS 
are generally considered to be opportunistic bacteria inhabiting teat skin 
and canals (Taponen et al., 2008). Nevertheless, the presence of  CNS 
and C. bovis in the milk samples alone could increase concentrations of  
APP and NAGase activity in the milk, indicating that these bacteria are 
able to invade the udder and induce an infl ammatory reaction. The PCR 
method allows the quantitative detection of  udder pathogens, and is 
especially useful when bacteria are present in low quantities and may 
be undetectable using conventional methods. On the other hand, the 
high sensitivity of  the PCR analysis and the methods used to collect 
milk samples can cause false-positive results, especially in large herds 
when many staff  members are involved in the sampling. Presence 
of  microbes in a milk sample does not necessarily prove that those 
microbes caused the intramammary infection. Interpretation of  PCR 
results can be challenging and would need more guidance, even though 
PCR-based diagnostics is already in routine use in some countries. In the 
interpretation of  PCR results, detection of  a single species, preferably in 
moderate or large quantities, or detection of  one dominating species with 
some other species provides a likely bacteriological diagnosis. The fi nal 
diagnosis of  mastitis always requires a full complement of  supporting 
information, such as knowledge of  the clinical signs and infl ammation 
in the quarter (Pyörälä, 2012).
In this study, Hp performed better than MAA in describing bovine 
infl ammatory response. A constant increase in concentrations of  Hp 
in the milk along with increasing quantities of  DNA (except CNS and 
C. bovis) was observed. Hp could thus be a better marker than MAA for 
indicating the local infl ammatory response in clinical mastitis caused by 
different pathogens. 
6.5. Effi cacy of  treatment of  clinical mastitis caused by Gram-
positive bacteria (IV)
The outcome of  benzylpenicillin treatment of  clinical mastitis 
caused by Gram-positive bacteria susceptible to penicillin in vitro 
was not affected by the route of  administration of  the drug. Clinical 
64
studies comparing the effi cacy of  parenteral and IMM treatment for 
clinical mastitis are in general rare. To the authors’ knowledge, fi eld 
trials comparing the effi cacy of  parenteral and IMM benzylpenicillin 
treatment of  bovine clinical mastitis have not been published. Parenteral 
penethamate hydroiodide treatment was compared to IMM penicillin-
dihydrostreptomycin treatment in a study performed in New Zealand, 
and no signifi cant differences were observed (McDougall, 1998). The 
majority of  mastitis cases in that study were caused by Str. uberis, a 
species susceptible to benzylpenicillin. Sérieys et al. (2005) compared 
treatment with parenteral penethamate to IMM ampicillin-cloxacillin, 
with no signifi cant differences between the two treatment regimens. 
Specifi c information regarding the in vitro susceptibility of  the causative 
agents was not available, and no real comparison can be made. In clinical 
mastitis experimentally induced by Str. uberis and treated with penicillin, 
bacteriological cure did not differ between IMM, parenteral or combined 
treatment groups; however, the groups were so small that no conclusions 
could be made (Hillerton and Kliem, 2002). The dose of  benzylpenicillin 
procaine used in that study was half  of  that used in our study, which 
could affect the parenteral cure rates. No differences between parenteral 
benzylpenicillin and IMM penethamate were found for the treatment of  
subclinical mastitis caused by penicillin-sensitive S. aureus or streptococci 
(Hallen-Sandgren et al., 2008). In an old U.S. study, the effi cacy of  IMM 
amoxicillin alone or combined with intramuscular benzylpenicillin was 
compared for the treatment of  subclinical S. aureus mastitis (Owens et 
al., 1988). Bacteriological cure rates were approximately 50% and did 
not differ between the treatments; however, because no information 
regarding penicillin susceptibility was available, drawing any conclusions 
is diffi cult.
Overall, the bacteriological cure rates of  clinical mastitis caused by 
staphylococci and streptococci treated with different antimicrobials 
and routes of  administration have ranged from 56% to 84% (Jarp et al., 
1989; Taponen et al., 2003a; Serieys et al., 2005; McDougall et al., 2007; 
Apparao et al., 2009; Bradley and Green, 2009, Ruegg, 2010). Taponen et 
al. (2003a) used a 4-day treatment with IMM benzylpenicillin for mastitis 
caused by penicillin-susceptible Gram-positive bacteria, and reported a 
clinical cure rate of  75% and a bacteriological cure rate of  73%. The 
clinical cure rate was similar to our study, but the bacteriological cure 
rate was approximately 20% higher than in the present study, which may 
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be due to the different clinical severity of  mastitis or different methods 
used for the bacteriological follow-up. Jarp et al. (1989) reported a total 
bacteriological cure rate of  68% for clinical mastitis due to Gram-positive, 
penicillin susceptible bacteria, treated for 5 days with benzylpenicillin, 
using the same dose as here. The cure rate of  that study was also higher 
than reported in our study, possibly due to the same reasons as mentioned 
earlier. Bacteriological cure rates of  mastitis depend on the causative 
agent. McDougall et al. (2007) compared treatment of  clinical mastitis 
with three different IMM products, one of  them containing procaine 
penicillin alone. More than half  of  the cases were caused by Str. uberis, 
and treatment with penicillin IMM for 1.5 d resulted in a cure rate as high 
as 91%, which is much higher than found here. Different conditions in 
the New Zealand such as much lower average milk production and less 
severe clinical signs may at least partly explain the difference.
Mastitis causing streptococcal species have remained susceptible to 
benzylpenicillin (Pitkälä et al., 2004; Hendriksen et al., 2008; Bengtsson 
et al., 2009). S. aureus and CNS isolated from bovine mastitis have 
developed resistance to penicillin (Hendriksen et al., 2008; Bagcigil et 
al., 2012), which may signifi cantly infl uence the effi cacy of  treatment 
(Pyörälä and Pyörälä 1998; Sol et al.; 2000; Taponen et al., 2003b). In our 
study, 6 of  8 cases of  mastitis caused by penicillin-susceptible S. aureus 
were cured using either intramuscular or IMM penicillin treatment. The 
bacteriological cure of  20 quarters with mastitis caused by penicillin-
resistant S. aureus treated for 5 days with cloxacillin was in the present 
study zero (data not shown). It is known that mastitis caused by 
penicillin-resistant S. aureus is diffi cult to cure (Taponen et al., 2003b; 
Barkema et al., 2006). The poor treatment response of  these cases is 
mainly not derived from antibiotic resistance. The ability of  penicillin-
resistant S. aureus isolates to cause persistent infections may be due to 
several virulence factors, possibly linked to the β-lactamase gene of  the 
resistant isolates (Haveri et al., 2005; Van den Borne et al., 2010). In the 
treatment of  mastitis, tested or assumed in vitro susceptibility of  the 
causing bacteria is considered a prerequisite for the use of  a particular 
antibiotic, but pre-treatment susceptibility is not always predictive of  
treatment response in vivo (Barlow, 2011).
Benzylpenicillin is a weak acid, which after parenteral administration 
penetrates poorly into the mammary gland. However, because the MIC 
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values for susceptible organisms are generally very low (≤0.12 μg/ml for 
staphylococci and ≤0.06 μg/ml for streptococci (Prescott et al., 2007; 
Bengtsson et al., 2009), it is possible to achieve and maintain therapeutic 
concentrations in the milk using parenteral administration of  20 mg/kg 
benzylpenicillin procaine once a day as used in this study (Franklin et al., 
1984; Ziv and Storper, 1985).
IMM infusion results in concentrations as high as 100-1000-fold of  
those obtained with parenteral administration, which is advantageous 
for infections of  the milk compartment, such as streptococcal mastitis 
(Moretain et al., 1989; Erskine et al., 2003). The total dose of  antimicrobials 
administered via the IMM route is considerably lower than that in 
parenteral treatment. Furthermore, painful injections can be avoided. 
When infusing IMMs containing narrow-spectrum antimicrobials 
antibiotics such as benzylpenicillin, strict hygienic measures should 
be used to avoid inducing mastitis (Middleton and Luby, 2008). IMM 
administration is the route of  choice for mastitis caused by streptococcal 
species, which reside in the milk compartment (Erskine et al., 2003; 
Guardabassi et al., 2008). Parenteral or combined treatment has been 
suggested for mastitis caused by S. aureus (Erskine et al., 2003; Constable 
et al., 2008). Taponen et al. (2003b) reported a bacteriological cure of  
72% for mastitis caused by penicillin-susceptible S. aureus treated with 
5-day combined parenteral and IMM treatment with penicillin. In our 
study, no difference was observed between the two routes of  treatment, 
but the S. aureus group was too small to draw any conclusions. Our 
group infected with CNS was also small, but based on the literature, 
IMM is the route of  choice in the treatment of  CNS mastitis (Erskine et 
al., 2003; Pyörälä and Taponen, 2009).
In this study, bacteriological diagnosis was based on a PCR assay. For 
the evaluation of  the bacteriological cure, strict criteria were used. If  
DNA of  the same species detected before treatment was found alone or 
together with the DNA of  other species in the post-treatment sample, 
the case was classifi ed as not cured. It is known that the PCR-based assay 
is more sensitive than a conventional culture (Koskinen et al., 2010). This 
may be refl ected as lower percentages of  cure than in previous studies 
in which conventional culturing was used for assessment. Excluding all 
samples with more than one species from the analysis would result in 
the discarding of  a considerable number of  cases, because the PCR test 
often detects more than one species (Koskinen et al., 2010). 
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Higher cure rates may have also been expected here because our 5-day 
treatment is longer than standard treatments used for mastitis in many 
countries. Longer treatments have been reported to result in higher cure 
rates, at least for mastitis caused by S. aureus and Str. uberis (Jarp et al., 
1998; Oliver et al., 2004; Deluyker et al., 2005; Krömker et al., 2010). 
Recently, 5-day treatment with cefquinome did not increase cure rates 
in clinical S. aureus mastitis compared with 1.5-day treatment (Swinkels 
et al., 2013). This discrepant result may be due to the drug used or 
differences in the virulence of  the bacterial strains causing IMIs. In 
assessing cure rates, the possibility of  contamination of  the sample with 
the same species as detected in the pre-treatment sample should also 
to be taken into account. This could lead to a false positive sample and 
false classifi cation of  the case as not cured. However, this affects both 
conventional and PCR-based tests. If  PCR assays are used to assess the 
outcome in treatment trials of  mastitis, some adjustments to the tests 
may be necessary for the interpretation of  results.
Combining bacteriology with some indicator of  infl ammation in the 
milk would be useful for confi rming the assessment (Green and Bradley, 
2010). The most common indicator used to monitor the infl ammatory 
status of  the udder is milk SCC. Milk NAGase activity is another 
good choice for this purpose (Pyörälä, 2003). NAGase originates 
from somatic cells but also from damaged epithelial cells (Mattila and 
Sandholm, 1986; Pyörälä, 2003). It correlates well with milk SCC and 
has the advantage that freezing the milk samples does not interfere with 
the analysis (Pyörälä, 2003). The threshold values of  these parameters 
should perhaps be adjusted for this purpose, because the infl ammatory 
reaction of  the quarter may last longer than elimination of  the infection. 
The threshold levels of  the markers used for screening of  mastitis may 
be too high for monitoring the recovery of  the quarter (Pyörälä and 
Pyörälä, 1997). 
Generally, two post-treatment samples are recommended for the 
bacteriological evaluation of  cure (Schukken and Deluyker, 1995). 
Here, only one sample was collected for practical reasons, but we used a 
sensitive PCR assay for bacteriology, which could somewhat compensate 
the lack of  the second sampling. Including the cow survival data and 
cow composite milk SCCs follow-up provides information regarding the 
long-term effects of  the treatments and can be recommended for fi eld 
trials of  mastitis. In the present study, the CMSCCs remained higher 
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and the proportion of  low CMSCC cows was numerically smaller in 
the IMM-treated group, even though no signifi cant differences between 
the groups were found. A possible explanation for this result is that the 
cows had other quarters with subclinical IMI, which were also treated 
when the treatment was administered parenterally and this may have 
affected cow CMSCCs.
6.6. Antimicrobial resistance of  clinical mastitis pathogens (II)
The disc diffusion method for in vitro antimicrobial susceptibility testing 
was used to determine antimicrobial resistance of  clinical mastitis 
pathogens in Study II. This technique is the most widely used method 
for determination of  the susceptibility of  animal pathogens, especially 
in clinical work when it is necessary to determine the correct treatment. 
The primary disadvantage of  using this method when monitoring 
development of  resistance is that outcomes are reported on a qualitative 
basis (sensitive, intermediate, or resistant), and subtle changes in 
susceptibility may not be apparent. Therefore any comparison with 
studies that use other methods of  susceptibility testing is not acceptable 
(Schwarz et al., 2009). Generally, in our study, the in vitro antimicrobial 
resistance of  the isolates examined from samples of  clinical mastitis was 
high. Isolates of S. aureus had an alarming level of  resistance to penicillin 
(61.4%) and ampicillin (59.5%), whereas CNS exhibited a lower degree 
of  resistance (38.5% and 34.4%, respectively). The reported percentages 
for penicillin-resistant S. aureus in cases of  clinical mastitis, detected by 
the disc diffusion method, were 50.4% and 35.4% in the two US studies 
(Erskine et al., 2003; Makovec and Ruegg, 2003), 63.3% in Turkey (Güler 
et al., 2005), and 12% in Northern Germany (Schröder et al., 2005). In 
addition, cephalotin resistance among staphylococci was found in our 
study. As there is little published information on methicillin-resistant 
staphylococci causing bovine mastitis, the relevant samples found in our 
study need further investigation to prove or exclude the presence of  the 
mecA gene. In this study, both staphylococci and streptococci showed 
resistance to erythromycin and lincomycin, but the fi gures for resistance 
in annual reports from some other countries show a low prevalence of  
lincomycin and erythromycin resistance in S. aureus and CNS (SVARM, 
2004; NORM/NORMVET, 2003; MARAN, 2008). Given that S. aureus 
and CNS were the pathogens isolated most frequently from cases of  
subclinical mastitis, one possible explanation for resistance to several 
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antibiotics may be the collection and submission to the laboratory of  
milk samples from chronic clinical mastitis (which demonstrate poor 
treatment effi cacy). Therefore, random sampling strategies should be 
used to provide a good evaluation of  antimicrobial susceptibility.
The level of  resistance of  E. coli and Klebsiella spp. was high against all 
tested antimicrobials, except cefaperazone and enrofl oxacin. Coliforms 
are often resistant to more than one antimicrobial (Lehtolainen et al., 
2002; Bengtsson et al., 2009), and the number of  multiresistant strains 
may infl uence the resistance fi gures. Coliform bacteria isolated from 
cases of  mastitis may refl ect the general situation of  resistance in the 
herd, and can be considered more as an indicator of  the bacteria present 
than an indicator of  specifi c pathogens from the udder (Lehtolainen 
et al., 2002). All the bacterial species investigated in this study showed 
resistance to tetracycline. A possible explanation for this phenomenon 
could be the fact that tetracycline has been the class of  antimicrobials 
most widely used for treatment of  several infections for many years. 
Furthermore, tetracycline has been found in multiresistant patterns with 
penicillin and streptomycin (Lehtolainen et al., 2002; Güler et al., 2005). 
According to the data provided by the Estonian State Agency of  
Medicines, a total of  209,880 single intramammary syringes for 
lactating cows and 205648 for dry cow therapy were sold in the year 
2009. Ampicillin and cloxacillin combinations, cephalosporins with 
aminoglycosides, and lincomycin with neomycin were the most common 
choices for the treatment of  mastitis in lactating cows. For example, 255 
grams of  intramammary lincomycin (pure antimicrobial) and 44.2 grams 
of  intramammary cephalosporins per thousand dairy cows were sold 
for the treatment of  clinical mastitis in 2009. However, only 73.4 grams 
of  penicillin G was used per thousand dairy cows for intramammary 
treatment of  clinical mastitis. The use of  broad-spectrum antibiotics 
and antibiotic combinations may infl uence the resistance of  mastitis 
pathogens. Moreover, bacteriological examination of  milk samples 
before treatment of  clinical mastitis is not a common practice in 
Estonia. According to the data available in Sweden, intramammary and 
intramuscular penicillin G (Landin, 2006) are used in over 80% of  cases 
for treatment of  clinical mastitis, but the prevalence of  resistance of  
S. aureus to penicillins is only 7.1% (Bengtsson et al., 2009). In Finland, 
penicillin G and some broad-spectrum β-lactam antibiotics are used 
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in the treatment of  clinical mastitis, but the prevalence of  resistance 
in S. aureus is around 13% (Nevala et al., 2004; Thomson et al., 2008). 
Bacteriological examination before treatment is common in both 
countries. Considering these results, we can assume that the main reason 
for the occurrence of  a high number of  resistant strains in Estonian 
herds is the wide use of  broad-spectrum antimicrobials and long-term 
keeping of  infected cows in the herd.
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7. CONCLUSIONS
  The most frequently isolated udder pathogens in primiparous 
cows were E. coli, Str. uberis and coagulase-negative staphylococci, 
while S. aureus was the predominant pathogen observed in 
multiparous cows with clinical mastitis at parturition. The 
udder pathogens isolated from primiparous dairy cows on tie-
stall farms did not differ signifi cantly from those of  free-stall 
farms, whereas differences were found between primiparous 
and multiparous cows at parturition.
  The incidence rate of  clinical mastitis in freshly calved heifers 
was 6.4%. Housing system was not a signifi cant risk factor for 
clinical mastitis in freshly calved heifers. As regards the tie-stall 
farms, moving heifers to the cowshed less than two weeks prior 
to calving increased the risk for clinical mastitis at parturition. 
  The quantity of  bacterial DNA in a milk sample was associated 
with the concentrations of  APP and NAGase activity in the milk. 
These indicators refl ect the extent of  infl ammatory reaction 
in the mammary gland, as APP concentrations and NAGase 
activity increase along with the increase in severity of  mastitis.
  Concentrations of  APP and NAGase activity in the milk differed 
signifi cantly between different mastitis-causing bacterial species. 
The MAA and Hp concentrations in milk and NAGase activity 
were signifi cantly higher in the samples containing large amounts 
of  bacterial DNA from E. coli or Str. dysgalactiae compared with 
mastitic milk samples not containing these species. High bacterial 
DNA concentrations from T. pyogenes or Str. uberis were associated 
with elevated concentrations of  Hp and a high NAGase activity, 
but not with increased MAA concentrations. The milk samples 
containing C. bovis and coagulase-negative staphylococci had 
signifi cantly lower concentrations of  MAA and Hp and lower 
NAGase activity than the samples in which these species were 
not detected.
  The most frequently isolated pathogens from the cases of  
clinical were Str. uberis followed by E. coli and S. aureus. mastitis 
in 2007-2009 in Estonia. Most cases of  subclinical mastitis were 
caused by S. aureus and CNS. 
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  The probability of  isolating S. aureus from milk samples was 
signifi cantly higher on the farms with less than 30 cows, compared 
with those housing more than 100 cows. A signifi cantly higher 
risk of  infection Str. agalactiae was observed on the farms with 
herds over 600 cows, compare to smaller farms. 
  The in vitro antimicrobial resistance of  the isolates examined 
from the samples of  clinical mastitis was high. Isolates of  S. 
aureus had an alarming level of  resistance to penicillin (61.4%) 
and ampicillin (59.5%), whereas CNS exhibited a lower degree 
of  resistance (38.5% and 34.4%, respectively). The level of  
resistance of  E. coli and Klebsiella spp. was high against all tested 
antimicrobials, except cefaperazone and enrofl oxacin. A general 
decline in the antimicrobial resistance levels in cattle in Estonia 
should be highlighted. Appropriate guidelines for antibiotic 
usage should be developed and implemented, to help veterinary 
surgeons make pathogen-specifi c treatment decisions.
  The outcome of  parenteral or intramammary penicillin 
treatment of  mastitis caused by penicillin-susceptible bacteria 
was determined to be similar. 
  Intramammary treatment could routinely be used for the 
treatment of  clinical mastitis caused by streptococcal species. 
Streptococci reside in the milk compartment, and there are no 
pharmacokinetic grounds for the use of  parenteral administration 
of  the antimicrobial. Parenteral treatment is more invasive and 
signifi cantly increases dose of  the antimicrobial. 
  With a more sensitive PCR method, bacteriological cure rates 
may be lower, which should be considered by researchers, the 
pharmaceutical industry and authorities in the future.
  If  PCR tests are used to assess the outcome of  the treatment trials, 
it may be necessary to adjust some of  the criteria for interpreting 
the results. It might be worthwile to use some indicators of  
infl ammation in the milk to completement bacteriology.
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9. SUMMARY IN ESTONIAN
Kliiniliste mastiitide diagnoosimine, ravi tulemuslikkus ja 
patogeenide antimikroobne resistentsus Eestis
Piimakarjakasvatus on üks tähtsamaid põllumajandusharusid Eestis. 
Lüpsilehmade tervise säilitamine ja kvaliteetse piima tootmine suurendab 
Eesti piimatoodete konkurentsivõimet nii Euroopa kui ka maailma 
turul. Mastiit ehk udarapõletik on piimalehmade levinuim haigus, 
põhjustades suurt majanduslikku kahju, eeskätt suurenenud ravikulude, 
saamatajäänud piima ja lehmade enneaegse karjast praakimise tõttu.
Peamiseks põletiku vallandajaks udaras on nisajuha kaudu udarasse 
tunginud mikroobid. Udara vastuvõtlikkust nakkusele soodustavad 
lehma vähenenud vastupanuvõime, puudulik lüpsihügieen ja ebasoodsad 
keskkonnatingimused. Organismi vastureaktsiooniks eri udaranakkustele 
on erineva raskusastmega põletiku tekkimine. Mastiidid jagatakse 
kliinilise avaldumise alusel kliinilisteks ja subkliinilisteks. Kliiniliseks 
mastiidiks nimetatakse põletikku, mille korral vähemalt üks järgnevalt 
loetletud tunnustest on kliinilisel uurimisel nähtav: üldhaigestumise 
tunnused (palavik, isutus), lokaalsed tunnused (udara kuumus, paistetus, 
valulikkus) või makroskoopilised muutused haigestunud udaraveerandi 
sekreedis (vesisus, kämbud, helbed). Subkliinilise mastiidi korral kliinilised 
haigustunnused puuduvad, kuid piimas on põletikuindikaatorite 
sisaldus suurenenud. Peamiseks määratavaks põletikuindikaatoriks on 
somaatiliste rakkude arv (SRA). Rahvusvahelise Piimandusföderatsiooni 
(IDF) soovituste kohaselt loetakse udaraveerand põletikuliseks, kui 
udaraveerandi SRA on piimas üle 100 000 raku milliliitri kohta ja piimast 
isoleeritakse haigusttekitav mikroob.
Tänapäeval on teada üle 150 mastiiti põhjustava mikroobiliigi, kuid 
nendest 18–20 mikroobiliiki põhjustavad ligikaudu 90% kõikidest 
kliinilistest ja subkliinilistest mastiidijuhtudest. Udarapatogeenide 
mikrobioloogilise diagnoosimismeetodi kõrval on väga kiiresti arenemas 
molekulaarsed diagnostikameetodid. 2010. aastast saadik on nii Eestis 
kui ka mitmel pool maailmas rutiinselt kasutusele võetud polümeraasi 
ahelreaktsiooni (PCR)-meetodil põhinev mastiididiagnostika. See väga 
tundlik ja spetsiifi line diagnostikameetod võimaldab piimaproovist 
määrata 11 erinevat mastiidipatogeeni ja beetalaktamaasi produktsiooni 
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kodeerivat geeni. Kuivõrd mitmed udaranakkusi põhjustavad 
mikroobid elavad ka terve lehma nisa nahal või lehmi ümbritsevas 
keskkonnas, siis nende mikroobide tuvastamine piimaproovis võib olla 
põhjustatud proovi saastumisest. Seetõttu ei ole harv olukord, kus ühest 
piimaproovist määratakse enam kui ühe mastiidipatogeeni DNA ja 
selliste analüüsivastuste tõlgendamine on väga keeruline.
Kliinilise mastiidi esinemissagedus varieerub, sõltudes farmist ja isegi 
regioonist, kõikudes 2–60 juhuni 100 lehma kohta aastas. Subkliinilise 
mastiidi esinemissagedus võib olla veelgi suurem. Kliinilisse mastiiti 
võivad haigestuda igas vanuses ja laktatsioonijärgus olevad lehmad, 
kusjuures suurimat majanduslikku kahju põhjustab esimest laktatsiooni 
lüpsvate lehmade laktatsiooni alguses tekkiv kliiniline mastiit. 
Üldiselt arvatakse, et mullika udar on nakkusvaba ja udaratervisega 
seotud probleemid tekivad hiljem. Siiski näitavad mitmed uuringud 
udaranakkuste olemasolu mullikate udaras juba enne poegimist.
Lüpsilehmade ja -karjade arv Eestis on viimaste aastate jooksul vähenenud. 
Eesti Jõudluskontrolli Keskuse statistikast selgub, et 2009. aastal oli 
Eestis kokku 1024 veisekarja, kus peeti ligemale 95 000 lüpsilehma. 
2012. aastaks oli karjade arv 833, milles peeti kokku 90 274 lehma. 
1990. aastate keskpaigani peeti lehmi peamiselt lõastatult, kuid alates 
2000. aastast on järjest suurenenud vabapidamisega lüpsilautade osakaal. 
Vaatamata pidamisviisi muutmisele, uute lüpsiseadmete paigaldamisele ja 
hügieenivõtete täiustumisele farmides ei ole Eesti lüpsikarjade keskmine 
SRA oluliselt vähenenud. Samas ei ole Eestis senini täpsemalt uuritud 
kliiniliste mastiitide esinemissagedust, mastiiditekitajate jaotumist ega 
nende antibiootikumiresistentsust.
Kliiniline mastiit põhjustab lehmale valu, mistõttu õigeaegne ja adekvaatne 
ravi on lehma heaolu seisukohalt väga tähtis. Antibakteriaalse ravi 
eesmärgiks on kiire bakterite elimineerimine udarast ja seeläbi kudede 
kahjustuse vähendamine. Ligikaudu 70% kogu lehmadele manustatavast 
antibiootikumikogusest kasutatakse just mastiidiravis. Erinevaid 
antibakteriaalse ravi skeeme on mastiidiravis kasutatud enam kui 50 
aastat, kuid üksmeelt kõige efektiivsema, ohutuma ja majanduslikult 
parima ravi osas ei ole saavutatud.
Antibiootikumide pideva kasutamise negatiivse kõrvalmõjuna 
on mikroobidel arenenud resistentsus antibiootikumide suhtes. 
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Rahvusvahelised organisatsioonid, nagu Rahvusvaheline Episootiate 
Büroo (OIE) ja Maailma Terviseorganisatsioon (WHO), pööravad 
suurt tähelepanu resistentsusalase olukorra analüüsimisele ning mitmed 
riigid on välja töötanud juhendmaterjalid antibiootikumide otstarbekaks 
kasutamiseks loomadel. Eestis on viimastel aastatel mastiidiravis 
kasutatud valdavalt laia toimespektriga antibiootikume. Näiteks 2009. 
aastal oli kliinilise mastiidi raviks registreeritud 18 erinevat nisasüstalt, 
mis sisaldasid 15 erinevat toimeainet või nende kombinatsiooni. Laia 
toimespektriga antibiootikumide sage ja põhjendamatu kasutamine 
lehmadel võib kaasa tuua resistentsete mikroobide leviku, kelle levik 
inimestele on võimalik toiduahela kaudu.
Käesoleva uurimistöö eesmärgid olid:
1) hinnata esmaspoegijatel kliinilisse mastiiti haigestumise esinemust 
erinevate pidamistehnoloogiate korral ja selgitada välja kliinilise 
mastiidi haigustekitajad poegimise päeval nii esmaspoegijatel kui ka 
korduvpoegijatel (artikkel I);
2) leida seoseid kvantitatiivse PCR meetodiga diagnoositud kliinilist 
mastiiti põhjustavate mikroobide ja udaras tekkiva paikse 
põletikureaktsiooni vahel (artikkel II);
3) välja selgitada Eesti karjades levivad mastiidipatogeenid ja nende 
antibiootikumiresistentsus (artikkel III);
4) hinnata nisajuha kaudu ja lihasesisese penitsilliinravi tulemuslikkust 
grampositiivsete haigustekitajate põhjustatud kliinilise mastiidi korral 
(artikkel IV).
Esmaspoegijate ja korduvpoegijate kliinilise mastiidi hindamiseks 
koguti andmeid üheteistkümnest Eesti karjast üheaastase katseperioodi 
(2004–2005) jooksul. Kokku poegis katseperioodil 1063 mullikat ja 
2355 lehma. Läbiviidud juhtkontrolluuringus loeti juhtudeks (n = 68) 
kõik äsjapoeginud 1. laktatsiooni lehmad, kellel diagnoositi poegimise 
päeval kliiniline mastiit. Ülejäänud äsjapoeginud 1. laktatsiooni lehmi 
kasutati kontrollidena (n = 995). Kliinilise mastiidi diagnoosimise järel 
võeti kõikidelt esmas- ja korduvpoegijatelt steriilselt piimaproovid 
bakterioloogiliseks uuringuks. Logistilise regressioonanalüüsiga 
hinnati kliinilise mastiidi, laudatüübi ja mullikate poegimislauta viimise 
omavahelisi seoseid. X2 testiga hinnati esmas- ja korduvpoegijatelt 
isoleeritud haigustekitajate erinevust.
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Poegimise päeval diagnoositi kliiniline mastiit 6,4%-l esmaspoegijatest, 
mis on samaväärne teiste riikide uurimustulemustega. Risk haigestuda 
kliinilisse mastiiti oli üle kahe korra suurem (OR 2,44, p < 0,001) 
neil mullikatel, keda peeti lõaspidamisega lüpsilautades võrreldes 
vabapidamislautades poeginud mullikatega. Suurim risk haigestuda 
kliinilisse mastiiti poegimise päeval (OR = 3,74 p < 0,0001) oli nendel 
mullikatel, kes toodi lõaspidamisega lüpsilauta vähem kui kaks nädalat 
enne loodetavat poegimist. Vabapidamisega lüpsilauta toomise ja kliinilise 
mastiidi tekkimise vahel olulist seost ei leitud. Esmaspoegijate peamisteks 
udarapatogeenideks oli Escherichia coli (E. coli) (22,1%), Streptococcus uberis 
(Str.uberis) (19,1%) ja koagulaasnegatiivsed stafülokokid (KNS) (8,8%). 
Korduvpoegijatelt võetud piimaproovidest seevastu isoleeriti poegimise 
päeval kõige enam Staphylococcus aureus´t (S. aureus) (11,2%). E. coli, Str. 
uberis ja S. aureus olid haigustekitajad, mille esinemus poegimise päeval 
esmaspoegijatel ja korduvpoegijatel oluliselt erines. E. coli põhjustas enim 
kliinilisi mastiite vabapidamisega lüpsilautades, koagulaasnegatiivsed 
stafülokokid ja Str. uberis aga lõaspidamisega lüpsilautades. Statistiliselt 
olulist erinevust pidamistehnoloogiate ja mastiidipatogeenide esinemuse 
vahel siiski ei tuvastatud.
Väitekirja teine uurimus otsis seoseid kvantitatiivse PCR-meetodiga 
diagnoositud kliinilist mastiiti põhjustavate mikroobide ja udaras tekkiva 
paikse põletikureaktsiooni vahel. Piimaproovid (n = 281) koguti kliinilist 
mastiiti põdevatelt lehmadelt kolmest Eesti piimafarmist aastatel 
2007–2009. Piimaproovide bakterioloogiline analüüs viidi läbi PCR 
metoodikaga (Pathoproof  Mastitis PCR Assay, Thermo Fisher, Finland). 
Udara paikse põletikuvastuse hindamiseks määrati piimaproovidest ägeda 
faasi valgud: piima amüloidA (MAA) ja haptoglobiin ning kahjustatud 
udarakoest ja valgelibledest vabanev N-atsetüül-β-D-glükoosaminidaasi 
(NAGaas) aktiivsus. Logistilise regressioonanalüüsiga hinnati 
mastiidi kliiniliste tunnuste ja ägeda faasi valkude omavahelist seost. 
Lineaarse segamudeliga otsiti seoseid piima amüloidA ja haptoglobiini 
kontsentratsiooni, NAGaasi aktiivsuse ja PCR meetodil isoleeritud 
haigustekitajate vahel.
Kogutud 281st kliinilise mastiidi piimaproovist 28 proovi olid 
bakterioloogiliselt negatiivsed ja 27 proovi sisaldas enam kui nelja 
haigustekitajat (saastunud proovid). Allesjäänud 226 proovist tuvastati 
üks bakteriliik 68 proovis (30,1%), kaks bakteriliiki 99 (43,8%) ja kolm 
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bakteriliiki 59 (26,1%) proovis. Mida tugevamad oli kliinilised tunnused, 
seda suurem oli ka ägeda faasi valkude ja NAGaasi kontsentratsioon piimas. 
Uurimistulemused näitasid, et piimaproovis sisalduva haigustekitaja 
bakteriaalse DNA hulk ja udara paikne põletikuvastus on omavahel suurel 
määral seotud. Isoleeritud haigustekitajad põhjustasid erineva ulatusega 
põletikuvastuse. Nende udaraveerandite piimaproovides, kus leiti 
suures koguses E. coli või Streptococcus dysgalactiae (Str. dysgalactiae) DNAd, 
oli ägeda faasi valkude kontsentratsioon oluliselt suurem võrreldes 
nende udaraveerandite piimaproovidega, kus nimetatud baktereid ei 
esinenud. Udaraveerandites, kus oli suures koguses Trueperella pyogenes´e 
(T. pyogenes’e) ja Str. uberis’e bakteritest pärinevat DNAd, oli oluliselt 
suurem haptoglobiini ja NAGaasi aktiivsus, kuid MAA ei reageerinud 
peaaegu üldse. Piimaproovides, kus esines vähesel määral KNSi või 
Corynebacterium bovis’t (C. bovis) oli ka oluliselt väiksem ägeda faasi valkude 
ja NAGaasi aktiivsus võrreldes proovidega, kus neid bakteriliike ei leitud. 
Uurimistulemustest saab järeldada, et mida suurem oli piimaproovides 
E. coli, Str. dysgalactiae ja Str. uberis’e hulk, seda suurema tõenäosusega 
need bakterid põletikureaktsiooni esile kutsuvad. Kui piimaproovis on 
väiksemas kontsentratsioonis veel mõni bakteriliik lisaks, siis selle mõju 
põletikureaktsiooni tekkimisele on ebaoluline. KNSi ja C. bovis olemasolu 
proovis aga hoopis vähendas põletikureaktsiooni tugevust.
Eesti karjades levivate mastiidipatogeenide ning nende 
antibiootikumiresistentsuse väljaselgitamiseks kasutati 2007–2009 
aastatel Eesti veterinaar- ja toidulaboratooriumisse (VTL) saadetud 
kliiniliste ja subkliiniliste mastiitide korral võetud piimaproovide 
andmeid. Antibiootikumitundlikkust hinnati disk-difusiooni meetodil, 
kus grampositiivsetel mikroobidel määrati antibiootikumitundlikkus 
penitsilliini, ampitsilliini, tsefalotiini, klindamütsiini, erütromütsiini, 
gentamütsiini, trimetoprimi/sulfametoksasooli ja tetratsükliini 
suhtes. Gramnegatiivseid baktereid testiti ampitsilliini, gentamütsiini, 
trimetoprimi/sulfametoksasooli, tetratsükliini, enrofl oksatsiini, 
streptomütsiini, neomütsiini ja tsefaperasooni suhtes. Logistilise 
regressioonanalüüsiga hinnati bakterioloogilise uuringu tulemuse seost 
farmi suuruse, geograafi lise asukoha ja uuringuaastaga.
Kokku uuriti kolme aasta jooksul VTLis bakterioloogiliselt 3058t 
kliinilise mastiidi piimaproovi 190 karjast ja 5145t subkliinilise mastiidi 
korral võetud piimaproovi 274 karjast. Mastiiti põhjustavate mikroobide 
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puhaskultuurid isoleeriti 57%-l proovidest, bakterioloogiliselt 
negatiivsete proovide osakaal oli 22,3% ja segakasvuga proove kogunes 
20,6%. Mikroobide segakasvu sisaldavaid piimaproove oli palju rohkem 
subkliinilise mastiidi korral võetud piimaproovide hulgas võrreldes 
kliinilise mastiidi korral võetud proovidega. Seevastu tõenäosus leida 
bakterioloogiliselt negatiivne proov oli suurem kliinilise mastiidi korral 
võetud piimaproovidest. Kliinilisi mastiite põhjustasid enim Str. uberis 
(18,4%), E. coli (15,9%) ja Streptococcus agalactiae (Str.agalactiae) (11,9%), 
subkliinilisi aga S. aureus (20%) ja koagulaasnegatiivsed stafülokokid 
(15,4%). Str. agalactiae isoleeriti oluliselt sagedamini (p < 0,05) 
piimaproovidest, mis pärinesid üle 600 lehmaga farmidest. S. aureus’e 
esinemine seostus (p < 0,05) väikeste, alla 30 lehmaga farmidega. Selle 
uuringu tulemused näitasid, et Eestis on kliinilisi mastiite põhjustavate 
bakterite resistentsus antibiootikumide suhtes väga suur. Isoleeritud 
S. aureus’e (n = 174) resistentsus penitsilliini suhtes oli 61,6% ja 
koagulaasnegatiivsete stafülokokkide resistentsus (n = 173) 38,5%. 
Streptokokkide hulgas esines resistentsust tetratsükliini ja gentamütsiini 
suhtes. Suur oli ka stafülokokkide ja streptokokkide resistentsus 
makroliidide suhtes. E. coli isolaatidest 24,3%, 15,6% ja 13,5% olid 
resistentsed vastavalt ampitsilliini, streptomütsiini ja tetratsükliinide 
suhtes.
Väitekirja neljandas uurimuses hinnati kliinilise udarapõletiku korral 
läbiviidava lihasesisese ja nisajuhakaudse penitsilliinravi efektiivsust 
grampositiivsetesse haigustekitajatesse. Kliinilise mastiidi ravikatse 
viidi läbi neljas eesti lüpsikarjas 2007–2009 aastatel. Kliinilise mastiidi 
diagnoosimise järel võeti lehmalt piimaproov ja olenevalt ravirühmast 
alustati ravi kas lihasesisese või nisajuhakaudse ainult bensüülpenitsilliini 
sisaldava preparaadiga. Lihasesisesel ravil kasutati annust 20 mg/kg 
kehamassi kohta ja nisajuhakaudsel ravil 600 mg üks kord päevas. Ravi 
kestis mõlemas rühmas viis päeva. Kui esialgne bakterioloogiline uuring 
kinnitas gramnegatiivsete või penitsilliiniresistentsete stafülokokkide 
olemasolu, muudeti ravi. Lõplik piimaproovide bakterioloogiline 
uurimine viidi läbi PCR-metoodikal põhineva kommertsiaalse testiga 
(Pathoproof  Mastitis PCR Assay, Thermo Fisher, Finland). Lehma 
paranemist hinnati kolmandal või neljandal nädalal kliiniliste tunnuste, 
piimaproovi bakterioloogilise leiu ja põletikureaktsiooni muutuse alusel. 
Põletikureaktsiooni hindamiseks määrati piimaproovidest NAGasi 
aktiivsus. Uuringus olevatelt lehmadelt määrati üldpiima SRA kuue 
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ravijärgse kuu jooksul ja hinnati lehmade karjas püsimist. Logistilise 
regressioonanalüüsiga hinnati bensüülpenitsilliini manustamise 
koha (lihasesisene või nisajuhakaudne) mõju lehma kliinilisele ja 
bakterioloogilisele tervistumisele. Lineaarseid segamudeleid kasutati 
põletikureaktsiooni, bensüülpenitsilliini manustamise koha ja isoleeritud 
haigustekitajate omavaheliste seoste leidmiseks.
Kliinilise mastiidi ravikatses oli 140 lehma. Lihasesisesi raviti 
bensüülpenitsilliiniga 61 ja nisasisesi 79t penitsilliinitundlike 
udarapatogeenide põhjustatud mastiidijuhtu. Ülejäänud juhtudel (n 
= 32) kasutati raviks kloksatsilliini. Kokku tervistus kliiniliselt 108 
(77,1%) ja bakterioloogiliselt 77 (55.0%) bensüülpenitsilliiniga ravitud 
udaraveerandit. Uuringust selgus, et lehma kliiniline ja bakterioloogiline 
tervistumine ei sõltunud sellest, kas bensüülpenitsilliin manustati 
lihasesse või nisajuhasse. Põletikureaktsioon oli pärast ravi oluliselt 
nõrgem nendes udaraveerandites, kus bakterioloogiline leid oli negatiivne 
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Abstract
Background: Objectives of the study were to document the impact of some management factors
on the occurrence of clinical mastitis in primiparous dairy cows and to identify common udder
pathogens of clinical mastitis in freshly calved heifers and multiparous cows on the day of calving.
Methods: A one-year study was conducted during 2004 and 2005 in 11 selected Estonian dairy
herds. Data consisted of 68 heifers with clinical mastitis and 995 heifers without clinical mastitis on
the day of calving. Multivariable logistic regression with a random herd effect was used to
investigate any association between housing system or the time interval from movement of heifers
to the calving facility and day of calving on occurrence of clinical mastitis. Milk samples for
bacteriological analysis were collected from affected heifers and multiparous cows on the day of
calving
Results: Clinical mastitis occurrence in the study population of freshly calved heifers equalled 6.1
%. Housing system was not a significant risk factor for clinical mastitis of freshly calved heifers.
Moving heifers to the cowbarn less than two weeks before calving in tiestall farms increased risk
(OR = 5.9 p = 0.001) for clinical mastitis at parturition. The most frequently isolated udder
pathogens among heifers were Escherichia coli (22.1%), Streptococcus uberis (19.1%) and coagulase-
negative staphylococci (8.8%). In comparison, the main pathogen in multiparous cows with clinical
mastitis at parturition was Staphylococcus aureus (11.2%).
Conclusion: Moving heifers to the calving facilities too late in tiestall farms increased risk for
clinical mastitis at parturition. The isolated udder pathogens did not differ significantly in tiestall
farms compared to freestall farms in heifers, but differences were found between heifers and
multiparous cows at parturition.
Background
Mastitis is an economically important disease for dairy
cattle production worldwide. Although replacement heif-
ers are generally expected to have good udder health,
many studies have identified a high risk of their develop-
ing subclinical mastitis during early lactation and
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reported that the prevalence of intramammary infections
(IMI) is high in the peripartum period [1-7], mainly
depending on infectious species [8]. At the same time,
published reports on clinical mastitis incidence in freshly
calved heifers are scarce and controversial. A nested case-
control study in Norway showed that 5 % (6,410 out of
128,027) cases of clinical mastitis was treated in first calv-
ing heifers [9]. In Finland, the frequency of treatments for
heifer mastitis from one week before to one week after
calving was 3.9% for Ayrshires and 5.6% for Frisians [10].
In a study conducted in Netherlands the rate of clinical
mastitis around parturition was found to be higher in
heifers (>30%) compared to older cows (13%) [11].
Coagulase negative staphylococci (CNS), Streptococcus dys-
galactiae (Str. dysgalactiae) and coliforms have been the
most commonly identified pathogens of clinical mastitis
during the periparturient period in heifers [12,13]. How-
ever, in the studies conducted in Norway, Staphylococcus
aureus (S. aureus) was the most frequently isolated micro-
organism, followed by Str. dysgalacatiae and CNS [14]. At
the same time, differences have been found in occurrence
of staphylococcal mastitis between primiparous and mul-
tiparous cows, where CNS was more prevalent among
cows and S. aureus in freshly calved heifers [15]. Some
studies have suggested that udder pathogens found in
heifers close to parturition are similar to mammary path-
ogens found in lactating cows [1,12]. On the other hand,
the risk of S. aureus IMI was influenced by the amount of
time the heifers were housed with older cows and by the
proportion of S. aureus- infected cows in the herd [16]. In
Estonia, the most common pathogens of clinical mastitis
are S. aureus (20.5% of isolated bacteria), CNS (11%),
Streptococcus agalactiae (Str. agalactiae) (10.7%) and Strep-
tococcus uberis (Str. uberis) (10.5%) [17]. No data are avail-
able on udder health in freshly calved heifers and
multiparous cows in Estonia, although clinical mastitis
has frequently been observed at parturition. Management
factors at the herd level, including housing, feeding and
milking systems, affect the incidence of clinical mastitis
[18-21]; whereas at the individual cow level, milk leakage,
teat and udder oedema and blood in the milk are associ-
ated with mastitis incidence [22]. Both types of associa-
tions are dependent upon species of udder pathogens that
are present [23]. The transition phase, typically defined as
the period from 3 weeks before to 3 weeks after parturi-
tion, is viewed as a critical time in the lactation cycle of a
dairy cow. During this period, the cow experiences a series
of nutritional, physiological and social changes which
render her more vulnerable to infectious and metabolic
diseases [24].
The aims of this study were:
1) to study whether mastitis occurrence in first calving
heifers differs between farms with different housing sys-
tems and whether it is affected by the time interval
between movement of heifers to their calving facility and
their day of calving.
2) to identify common udder pathogens of clinical masti-
tis in first-calving heifers and multiparous cows on the day
of calving in Estonia
Methods
Study population and experimental design
The one year study was carried out during 2004 and 2005.
Eleven large-scale Estonian dairy herds was used in this
study. These herds were selected from among the herds
who received regular herd health visits by the university
large animal clinic (in total 25 herds). The herds having
more than 100 cows and 50 replacement heifers calving
per year were included into the study. In Table 1, the main
characteristics of the selected herds are presented. All heif-
ers that calved during the observation period (n = 1,063)
were eligible for inclusion. Heifers with clinical mastitis
on the day of calving were included as cases (n = 68), and
the remaining freshly calved heifers (n = 995) were con-
trols. Heifers on each farm were moved from their rearing
facility to the milking farm according to the availability of
space. The number of days between the day of transfer of
the heifer to the cowshed and the day of calving was
recorded.
Data collection in cases of clinical mastitis
Local trained veterinarians collected milk samples during
the first milking from all freshly calved heifers and mul-
tiparous cows on the day of calving. If milk from a quarter
had abnormal viscosity (watery, thicker than normal),
color(yellow, blood-tinged) or consistency(flakes or
Table 1: Characteristics of farms used in the study
Tied housing Loose housing
Number of herds 6 5
Average herd size (min; max) 259(200–350) 318(130–460)
Average milk yield per herd kg/305 d (min; max) 8056(5822–9130) 7194(6206–8061)
Total number of freshly calved heifers 423 640
Average number of calved heifers per herd (min; max) 71(50–82) 128(50–270)
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clots), clinical mastitis was diagnosed, and samples from
diseased udder quaters were collected for bacteriological
examination [25]. Before collection, the teat end was
cleaned with 70%-ethanol swabs and allowed to dry. After
discarding a few streams of milk, samples (2 to 4 ml) were
collected into sterile 10 ml plastic tubes, either frozen at -
20°C or cooled to +4°C and transported to the Estonian
Veterinary and Food Laboratory. All bacteriological exam-
inations of milk samples were performed according to the
standards of the National Mastitis Council [26].
Data analysis
Logistic regression with a random herd effect for control-
ling clustering was used to analyze the effect of housing
system (freestall, tiestall with short stall-length or tiestall
with long stall-length) and length of time before calving
that the heifers had been moved to the calving facility on
the occurrence of clinical mastitis. To simplify the model-
ling, the continuous variable, number of days from mov-
ing heifers to the calving facility and expected parturition,
was transformed to a dichotomous variable (≤14 days vs.
>14 days classes) in the model. Odds ratios (OR) with a
95% confidence interval (95% CI) were calculated. Statis-
tical significance was assumed at p ≤ 0.005. These analyses
were conducted using Stata 9.2 [27]. A two-sample pro-
portion test was used to estimate statistical significance of
differences in occurrence of udder pathogens between
first-calving heifers and multiparous cows. These analyses
were conducted using statistical software Statistix for Win-
dows 2.0.
Results
Approximately 40% (423) of the first-calving heifers were
in tiestall farms and approximately 60% (640) were in
freestall farms. The overall occurrence of clinical mastitis
at calving of the heifers was 6.4% (n = 68), being 9.7% (n
= 41) in tiestall farms compared with 4.1 % (n = 27) in
freestall farms. The range of days from moving heifers to
the calving facility and expected parturition were from 0
to76, where the median day was 26. The results of logistic
regression analysis are shown in Table 2. Housing system
only was not a significant risk factor for clinical mastitis of
freshly calved heifers. In tiestall farms heifers moved to
the calving facility less than two weeks before expected
parturition had a higher risk (OR = 5.9 p = 0.001) to
develop clinical mastitis at calving than heifers moved
more than 14 days before calving.
In total, 303 clinical mastitis cases were identified on the
day of parturition in 2,355 multiparous cows (12.8%).
Udder pathogens were isolated from 49 (72%) out of 68
cases of clinical mastitis in freshly calved heifers and from
185 (61%) out of 303 cases in multiparous cows.
Bacteriological findings are shown in Table 3. The most
frequently isolated bacteria from milk samples of freshly
calved heifers were E.coli and Str. uberis. No clinical masti-
tis caused by Str. agalactiae or Corynebacterium spp. was dis-
covered, and only one case of S. aureus mastitis was found
in heifers. In contrast, S. aureus was the most common
bacterium isolated from milk of affected multiparous
cows, followed by Str. uberis and Escherichia coli(E. coli).
Occurrence differences between heifers and cows were sta-
tistically significant for Str. uberis (p = 0.037), coliforms (p
= 0.0002) and S. aureus (p = 0.019).
Figure 1 shows the distribution in tiestall vs. freestall
housing systems of udder pathogens isolated from quarter
milk samples with clinical mastitis in freshly calved heif-
ers.
Table 2: Summary of logistic modelling of risk factors for clinical mastitis in heifers on the day of calving in eleven Estonian dairy 
herds.
Risk factor Number of cases(n = 68) Number of controls(n = 995) OR1 95% CI OR2 P-value
Model 1
Tiestall, short stall-length (≤ 175 cm), vs. tiestall, long stall-length 
(> 175 cm)
27/14 214/168 2.12 0.32–14.2 0.43
Freestall vs.tiestall, long stall-length 27/14 613/168 0.60 0.09–3.75 0.58
Model 2
Freestall 27 613 0.39 0.85–1.83 0.237
Tiestall 41 382 1
>14 day between movement to calving facility and day of calving 32 419 3.39 1.42–8.07 0.006
>14 days between movement to calving facility and day of calving 36 576 1
Tiestall and >14 days 16 260 1
Tiestall and ≤14 days 25 122 5.91 1.98–17.66 0.001
Freestall and >14 days 20 284 0.78 0.13–4.57 0.79
Freestall and ≤14 day 7 329 1.08 0.16–7.05 0.94
1 Odds ratio
2 95% confidence interval odds ratio
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In tiestall herds, 36.6% (n = 15) of the samples were bac-
teriologically negative or mixed cultures, while the corre-
sponding proportion in freestall herds was 14.8% (n = 4).
The most common udder pathogens in both housing sys-
tems were Str. uberis, E. coli and CNS. Occurrence of coli-
mastitis was higher in freestall farms than in tiestall farms,
but Str. uberis was more frequent in tiestall farms than
Table 3: Bacterial species isolated from milk samples from heifers and multiparous cows having clinical mastitis at parturition
Heifers Cows
Pathogens % n % n
E.coli* 22.1 15 6.6 20
Str. uberis* 19.1 13 9.9 30
CNS 8.8 6 7.3 22
Lactococcus lactis 4.4 3 5.0 15
Klebisella spp. 4.4 3 2.3 7
Str. spp 2.9 2 3 9
Enterococcus spp 2.9 2 2.3 7
Pseudomonas spp 2.9 2 0.7 2
S.aureus* 1.5 1 11.2 34
Arcanobacterium spp 1.5 1 2.6 8
Str.dysgalactiae 1.5 1 3.6 11
Corynebacterium spp 0 0 2.0 6
Str. agalactiae 0 0 3.3 10
Candida spp 0 0 1.3 4
No growth 25 17 29.4 89
Mixed culture 2.9 2 9.6 29
Total 100.0 68 100.0 303
* The difference between heifers and multiparous cows is statistically significant (
Distribution of udder pathogens in freshly calved heifers in two housing systemsFigure 1
Distribution of udder pathogens in freshly calved heifers in two housing systems. Detailed legend: *calculated against the total 
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freestall farms. The differences were not statistically signif-
icant.
Discussion
In 11 large herds using traditional Estonian dairy manage-
ment, two housing systems did not differ significantly in
clinical mastitis occurrence of first-calving heifers. Others,
however, have reported higher incidence of clinical masti-
tis in tiestall than in freestall housing [21,28-30]. In
tiestall farms, the main risk factors for clinical mastitis are
teat injuries, short stalls and shortage of bedding material
[31,32], especially during the periparturient period [33].
In one Swedish report, the incidence of clinical mastitis
decreased across 18 months, after the management sys-
tem was changed from the tiestall to the freestall system
[34]. We did identify an association at the tie-stall farms
between time of movement of close-to-term heifers to the
milking farm and the occurrence of clinical mastitis. Stress
and sudden changes in environmental and management
conditions during the peripartum period could weaken
natural defence mechanisms in animals, making them
more susceptible to clinical mastitis. In tiestall systems, an
increased frequency of lying down and rising may lead to
increased risk of teat tramping, leading to increased clini-
cal mastitis incidence [35]. Contrarily, in loose-housing
systems, cows have sufficient space for lying down and
standing up in a more natural way during parturition. The
results of the present study reflect the situation in large
commercial dairy herds in Estonia. However, the number
of herds in the study was limited and because sample sizes
were small in some herds, these results should be inter-
preted with caution. A larger study of longer duration and
with more herds is needed for more reliable conclusions.
In the relatively few reports on clinical mastitis in heifers,
occurrence of clinical mastitis has been variable. In Finn-
ish studies by Myllys [10], the treatment of clinical masti-
tis in heifers from one week before through one week after
calving increased from 1.8% to 4.4% between 1983 and
1991. In the USA, the incidence of clinical mastitis in heif-
ers was 12.3%, and mostly coliforms and streptococci
were isolated [36]. In 1,040 heifers, 1361 clinically
affected quarters were found in a large-scale Norwegian
study [14]. As to the present investigation, the occurrence
of clinical mastitis in freshly calved heifers was a modest
6.1%.
Environmental bacteria dominated in our study. Mainly
E.coli (22.1%), Str.uberis (19.1%) and CNS (9.2%) were
isolated in cases of clinical mastitis of the freshly calved
heifers. Similar results have been reported by others, in
which common bacteria isolated after parturition were
CNS, coliforms and streptococci [12,13,36].
In a Danish study, the most frequently isolated organism
was S. aureus [14]. Our investigation did not show S.
aureus clinical mastitis in freshly calved heifers, although
S. aureus was the main pathogen among the multiparous
cows. Despite that, the spread of this infection should not
be underestimated. Comparing tiestall and freestall farms,
the bacterial findings on the day of parturition were gen-
erally the same. Coliform infection was more common
among loose-housed heifers, where the primary source of
infection is bovine faeces and where the secondary multi-
plication of bacteria to high numbers in bedding and
manure is often a risk factor [38]. Prevalence of Str. uberis
infections depends on udder and calving hygiene, but
immune response in the lower udder gland also plays an
important role [37]. That might explain the higher preva-
lence of clinical mastitis in heifers. Altough more CNS
infections were found in tiestall farms, we could not draw
clear conclusions due to the small number of samples.
Our findings confirmed that S. aureus could be the main
pathogen causing mastitis in multiparous cows at the time
of parturition in Estonia. The importance of environmen-
tal bacteria may increase if management systems evolve
towards higher intensity of production.
Conclusion
Moving heifers to the calving fascilities too late in tiestall
farms, increased risk for clinical mastitis at parturition.
The isolated udder pathogens did not differ significantly
in tiestall farms compared to freestall farms in heifers, but
differences were found between heifers and multiparous
cows at parturition.
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 ABSTRACT 
 The associations between quantitative bacteriological 
results from a real-time PCR test and concentrations 
of acute-phase proteins (APP) and N-acetyl-β-d-
glucosaminidase (NAGase) activity in milk in naturally 
occurring clinical mastitis were investigated. Milk APP 
concentrations and NAGase activity in clinical mastitis 
caused by different udder pathogens were studied. The 
associations between the severity of the clinical signs 
and concentrations of APP and NAGase activity were 
estimated. Milk samples from 281 cases of clinical mas-
titis were collected from 3 Estonian dairy farms and 
analyzed by PCR to identify pathogens. Twenty-seven 
samples out of 281 (9.6%) were PCR negative. Milk 
samples containing 4 or more bacterial species (n = 
28) were considered possibly contaminated and ex-
cluded from all further analyses. In total, 443 bacterial 
identifications were made from the remaining 226 milk 
samples. A single bacterial species was detected in 68 
samples (30.1%), 2 species were detected in 99 samples 
(43.8%), and 3 species were detected in 59 (26.1%) 
samples. To determine the inflammatory response 
in the udder, the concentrations of milk amyloid A 
(MAA) and haptoglobin (Hp) and NAGase activity in 
the milk were analyzed. A significant positive associa-
tion was found between the severity of the clinical signs 
and inflammatory markers in the milk. Milk amyloid 
A and Hp concentrations and NAGase activity were 
significantly higher in samples with large quantities of 
bacterial DNA from Escherichia coli or Streptococcus 
dysgalactiae compared with milk samples not containing 
those species. Large quantities of bacterial DNA from 
Trueperella pyogenes or Streptococcus uberis in the milk 
were associated with elevated concentrations of Hp and 
high NAGase activity, but not with increased MAA 
concentrations. Milk samples containing Corynebacte-
rium bovis and coagulase-negative staphylococci had 
significantly lower concentrations of MAA and Hp and 
lower NAGase activity compared with samples where 
these species were not detected. It can be concluded 
that concentrations of APP and NAGase activity in 
the milk were associated with the quantity of bacterial 
DNA in the milk samples. 
 Key words:   clinical mastitis ,  acute-phase protein , 
N-acetyl-β-d-glucosaminidase (NAGase) activity ,  real-
time PCR 
 INTRODUCTION 
 Knowledge of the causative pathogens is required for 
appropriate control and treatment of mastitis. Bacte-
rial culture has been the gold standard for mastitis 
diagnostics (NMC, 2004), but a commercial PCR-based 
method has been introduced as a routine method for 
detection of mastitis-causing bacteria (PathoProof 
Mastitis PCR Assay; Thermo Fisher Scientific, Espoo, 
Finland). Due to the greater sensitivity of the PCR 
test compared with the conventional methods, often 
resulting in detection of more species per sample, the 
interpretation of the PCR results is challenging (Koski-
nen et al., 2010). More research concerning the use and 
interpretation of PCR mastitis tests in routine use is 
warranted. 
 Mastitis-causing bacteria entering the udder quarter 
via the teat canal, establish IMI with varying degrees 
of tissue injury. Tissue injury and inflammation initiate 
an acute-phase response (APR), which most commonly 
begins by releasing inflammatory mediators from tissue 
macrophages or blood monocytes that gather at the site 
of damage (Baumann and Gauldie, 1994; Koj, 1996). 
An APR results in an increase in systemic and local 
concentrations of acute-phase proteins (APP). Two of 
those proteins, haptoglobin (Hp) and serum amyloid 
A, play a significant role in the early response of the 
mammary gland to pathogenic bacteria (Eckersall et 
al., 2001; Nielsen et al., 2004). Haptoglobin is diffused 
from blood into the milk, but also originates from milk 
 Milk haptoglobin, milk amyloid A, and N D-glucosaminidase 
activity in bovines with naturally occurring clinical mastitis 
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leukocytes and epithelial cells in the mammary gland 
(Hiss et al., 2004). Serum amyloid A is secreted by 
hepatocytes and, in addition, the mammary gland epi-
thelium appears to secrete a mammary gland-specific 
isoform mammary-associated serum amyloid A 3 (M-
SAA3) milk amyloid A (MAA; Eckersall et al., 2001).
Local APR in the udder have mostly been studied us-
ing experimental models in which pathogenic bacteria 
such as Escherichia coli (Hyvönen et al., 2006; Suojala 
et al., 2008; Larsen et al., 2010) or staphylococci (Grön-
lund et al., 2003; Simojoki et al., 2009) have been in-
fused into the udder quarter. These studies showed that 
E. coli increases concentrations of APP in the milk to 
a greater extent than CNS or Staphylococcus aureus. A 
field study by Pyörälä et al. (2011) concluded that the 
concentrations of Hp and MAA in milk vary depending 
on which pathogens are isolated. Concentrations of APP 
were the highest in cases where mastitis was caused 
by E. coli and significantly lower when mastitis was 
caused by streptococci or Staph. aureus. Milk amyloid 
A and Hp inflammatory responses were very mild in 
mastitis caused by CNS. N-Acetyl-β-d-glucosaminidase 
(NAGase) is an intracellular, lysosomal enzyme that 
is released into milk from neutrophils during phagocy-
tosis and cell lysis, but also from damaged epithelial 
cells, indicating udder tissue destruction (Kitchen et 
al., 1984). Milk NAGase activity correlates very closely 
with SCC and can be analyzed also from frozen milk 
samples (Kitchen et al., 1984).
The first objective of the study was to investigate 
associations between different quantities of bacterial 
DNA detected using a PCR-based method and con-
centrations of APP and NAGase activity in milk from 
bovines with naturally occurring clinical mastitis. The 
second aim was to compare milk APP concentrations 
and NAGase activity in clinical mastitis caused by dif-
ferent udder pathogens and to study the effect of the 
severity of clinical signs.
MATERIALS AND METHODS
Milk Samples and Clinical Examination
Milk samples from cows diagnosed with clinical mas-
titis were collected for a treatment study, which was 
conducted during the period 2007 to 2009 in Estonia. 
Milk samples originated from 3 different loose-housing 
dairy farms. Herd sizes ranged from 300 to 1,000 cows. 
Among those herds, annual mean milk production was 
8,500 to 9,800 kg, and the average bulk milk SCC was 
between 180,000 and 450,000 cells/mL. All herds were 
milked 3 times per day. Clinical mastitis was diagnosed 
by trained farm personnel at milking time. Clinical 
mastitis was defined according to the International 
Dairy Federation (IDF, 1999), which specifies that at 
least some visible signs should be present in the udder 
or in the milk. Systemic and local signs were recorded 
and categorized on a 3-point scale as follows: (1) mild 
clinical mastitis: milk from a quarter had abnormal 
viscosity (watery or thicker than normal), color (yel-
low or blood-tinged), or consistency (flakes or clots), 
but no udder swelling or systemic signs; (2) moderate 
clinical mastitis: similar to mild clinical mastitis, but 
with the addition of visible or palpable changes in the 
udder (swelling or pain) without systemic signs; and (3) 
severe clinical mastitis: both local and systemic signs 
(fever above 39.2°C). All cow data (affected quarter, 
score of clinical mastitis, age, and DIM) were recorded.
Once clinical mastitis was diagnosed, a milk sample 
from the diseased udder quarter was collected for bac-
teriological examination. Before collection, the teat end 
was cleaned with 70% ethanol swabs and allowed to 
dry. After discarding a few streams of milk, samples (2 
to 4 mL) were collected into sterile 10-mL plastic tubes 
and frozen at −20°C until further investigation. Only 1 
diagnosed case of clinical mastitis per cow was included 
in the study.
During the study period, milk samples were collected 
from 35 cows at farm 1, 123 cows at farm 2, and 105 
cows at farm 3; a total of 281 quarter milk samples 
from 263 cows were included. Eighteen cows had 2 af-
fected quarters.
Real-Time PCR Assay
A commercial real-time PCR test kit (PathoProof 
Mastitis PCR Assay; Thermo Fisher Scientific) was 
used for direct analysis of all milk samples. The kit pro-
tocol involved 4 separate multiplex real-time PCR reac-
tions, which targeted 11 bacterial species and groups 
(covering more than 25 mastitis-causing species in to-
tal): Staphylococcus spp. (including Staph. aureus and 
all relevant CNS species), Enterococcus spp. (including 
Enterococcus faecalis and Enterococcus faecium), Cory-
nebacterium bovis, E. coli, Streptococcus dysgalactiae, 
Streptococcus agalactiae, Streptococcus uberis, Trueper-
ella (formerly Arcanobacterium) pyogenes/Peptoniphilus 
indolicus (Yassin et al., 2011), Klebsiella spp. (including 
Klebsiella oxytoca and Klebsiella pneumoniae), and Ser-
ratia marcescens. The testing was done according to the 
user’s manual and described by Koskinen et al. (2010). 
Based on the cycle threshold (Ct) values, the bacterial 
DNA quantity in each targeted bacterial species was 
grouped into 3 classes: small quantity (+), intermediate 
quantity (++), or large quantity (+++), according to 
the manufacturer’s manual.
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Analytical Methods for Determination  
of Inflammatory Response in Milk
The concentration of MAA in milk was determined 
using a commercial ELISA kit (Phase MAA Assay Kit; 
Tridelta Development Ltd., Maynooth, Co. Kildare, 
Ireland). Milk samples were initially diluted to 1:500. 
If the concentration was above the range of a stan-
dard curve, they were further diluted as necessary. For 
very high MAA values, milk samples were diluted up 
to 1:10,000 (maximum concentration 1,500 mg/L). A 
1:100 dilution was used (minimum concentration 0.94 
mg/L) for very low values. Intra- and interassay coef-
ficients of variation were <13 and <12%, respectively.
Milk Hp concentrations (mg/L) were determined 
by a method based on the ability of Hp to bind to 
hemoglobin (Makimura and Suzuki, 1982) and using 
tetramethylbenzidine as a substrate (Alsemgeest et al., 
1994). The assay is meant to determine concentrations 
of Hp in the serum, but was adapted here to be used 
for milk, as described by Hyvönen et al. (2006). Opti-
cal densities of the formed complex were measured at 
450 nm using a spectrophotometer. Lyophilized bovine 
acute-phase serum was used as a standard, and calibra-
tion was carried out according to the European Union 
concerted action on the standardization of animal APP 
(number QLK5-CT-1999-0153). The working range of 
the assay was 60 to 1,900 mg/L. The interassay and 
intraassay coefficient of variation values for Hp analysis 
were <8 and <13%, respectively.
Milk NAGase Activity Determination
Milk NAGase activity was measured by a fluoro-op-
tical method using an in-house microplate modification 
developed by Mattila and Sandholm (1985) and further 
modified by Hovinen et al. (2010). The calibrated milk 
sample was replaced with a control milk sample with 
a known 4-methyl-umbelliferon (4-MU) concentration, 
and NAGase activity was expressed as picomoles of 
4-MU/min per microliter of milk at 25°C. The upper 
detection limit for NAGase activity was 24.5 pmol of 
4-MU/min per microliter. Interassay and intraassay 
coefficients of variation for NAGase activity were 5 and 
4%, respectively.
Statistical Analysis
Stata 10.0 (StataCorp, TX) software was used for 
statistical analyses. Only milk samples with PCR-
negative results or ≤3 pathogen species were analyzed 
(n = 253). Generalized linear mixed models (GLMM) 
were used to investigate associations between milk APP 
and PCR results. The outcome variable MAA was loga-
rithmically transformed, and the inverse square root 
transformation of Hp was used. As Hp is evaluated us-
ing a model in inverse scale, negative model estimates 
represent higher Hp concentrations. The full models 
included lactation number as a 4-level categorical vari-
able (1, 2, 3, and ≥4 lactations), DIM was categorized 
as a 4-level variable according to quartiles (1–19, 20–59, 
60–118, and 119–412 DIM), farm as a 3-level variable, 
and affected quarter as a 2-level variable (fore and hind 
quarters). These variables were kept in all models to 
control possible confounding effects. As these variables 
were not significant in any of the models (except af-
fected quarters in the MAA model), they are not shown 
in our results. The PCR results by pathogen were in-
cluded as categorical variables (negative, +, ++, or 
+++). If PCR results were under 6 cases per level, 
they were consolidated with the previous factor level 
as follows: C. bovis ++ with C. bovis +; Strep. aga-
lactiae +++ with Strep. agalactiae ++; Strep. dysga-
lactiae +++ with Strep. dysgalactiae ++; T. pyogenes 
+++ with T. pyogenes ++; and CNS +++ with CNS 
++. To account for clustering of data (13 cows had 2 
samples from different quarters), cow was included as 
random factor. The Wald test was used to evaluate 
the overall significance of the categorical variables with 
more than 2 levels. Nonsignificant PCR result variables 
were removed using the stepwise backward elimination 
procedure. Both final models were tested for interac-
tions between minor pathogens (C. bovis and CNS) and 
major pathogens (E. coli, T. pyogenes, Strep. uberis, 
and Strep. dysgalactiae).
The random effects Tobit regression model for cen-
sored data was used to investigate associations between 
milk NAGase activity and PCR results. The Tobit re-
gression model was chosen because >40% of the NAGase 
results were over the maximum working limit of the 
assay (24.5 pmol of 4-MU/min per microliter), which 
would violate the regression model’s assumptions. In 
the Tobit regression, all cases falling above (or below) 
a specified threshold value are censored, although these 
cases remain in the analysis (Long, 1997). A more de-
tailed explanation using Tobit regression for analyzing 
milk NAGase activity data are given in Pyörälä et al. 
(2011). Square root transformation of milk NAGase ac-
tivities was used to achieve a normal distribution of un-
censored data; 104 samples were censored at the level of 
24.5 pmol of 4-MU/min per microliter. All other model 
building strategies and variables in each model were as 
described for the APP models above.
A linear regression model for APP and a Tobit re-
gression model for NAGase were used to investigate 
the associations of milk APP concentrations and milk 
NAGase activities with the severity of clinical mastitis 
(mild, moderate, and severe signs). Assumptions of all 
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models were controlled using normality and scatter 
plots of model residuals.
RESULTS
Bacteriological Findings
Ten different species of udder pathogens were detect-
ed in the 281 quarter milk samples using the real-time 
PCR kit. A total of 27 milk samples (9.6%) were PCR 
negative, and 254 (90.4%) samples contained DNA of 
at least 1 target species. Milk samples containing DNA 
of 4 or more bacterial species (n = 28) were considered 
possibly contaminated and excluded from further anal-
ysis. In total, 443 bacterial identifications were made 
from the remaining 226 milk samples. A single bacterial 
species was found in 68 (30.1%), 2 species were found 
in 99 (40.8%), and 3 species were found in 59 (26.1%) 
of the DNA-positive milk samples.
The most prevalent bacterial species among the milk 
samples containing a single pathogen were Strep. uberis 
(n = 20; 29.4%), Staph. aureus (n = 14; 20.5%), and E. 
coli (n = 13; 19.1%). Streptococcus uberis was detected 
in 45 (45.4%) and CNS was detected in 40 (40.4%) of 
the milk samples with 2 bacterial species.
Different quantities and proportions of mastitis-caus-
ing bacteria were detected in the milk samples (Table 
1). None of the milk samples contained 2 or 3 bacterial 
species in large quantities simultaneously. Of the 98 
milk samples containing DNA from CNS, the quantity 
was small (+) in 78 of them (85.7%). Bacterial DNA 
from Enterococcus spp. and Klebsiella spp. was detected 
rarely and only in small quantities.
Clinical Signs, APP, and NAGase Activity in Milk
In a total of 253 analyzed mastitis cases, 63.6% (n 
= 161) exhibited mild clinical signs and 31.2% (n = 
79) moderate clinical signs. Severe clinical signs were 
recorded in 5.1% (n = 13) of the cases. All samples 
collected from cows with severe mastitis were positive 
for bacteria, and E. coli was detected in 10 of the 13 
samples. Streptococcus uberis and CNS were the main 
bacterial species in moderate and mild clinical masti-
tis. Clinical signs in the cows yielding PCR-negative 
samples were moderate or mild.
The concentration of MAA in milk ranged between 
0.94 and 1,500 mg/L [median: 43.3 mg/L; interquartile 
range (IQR): 16.9–183.3 mg/L], and Hp varied from 59 
to 1,890 mg/L (median: 214.1 mg/L; IQR: 105.7–398.6). 
Of the 253 milk samples, 2 samples contained an MAA 
concentration below the working limits of the assay, and 
13 samples contained an MAA concentration above the 
working limits of the assay (0.94 and 1,500 mg/L, re-
spectively). Twenty-one samples had Hp concentrations 
under the working limit of the assay (59 mg/L). The 
activity of NAGase in milk ranged between 0.53 and 
24.5 pmol of 4-MU/min per microliter (median: 19.5 
pmol of 4-MU/min per microliter; IQR: 7.9–24.5 pmol 
of 4-MU/min per microliter), and in 104 milk samples, 
the NAGase activity was above the working range of 
the assay (24.5 pmol of 4-MU/min per microliter).
An association between the severity of clinical signs 
and the concentrations of APP and NAGase activity 
in the milk was found. In cases of severe clinical masti-
tis, MAA and Hp concentrations and NAGase activity 
values were significantly higher compared with cases 
of clinical mastitis with mild or moderate signs (P < 
0.001, P = 0.006, and P = 0.021, respectively). Con-
centrations of MAA and Hp and NAGase activity in 
milk from cows with moderate clinical mastitis were 
significantly higher than values measured in milk from 
cows with mild clinical signs (P < 0.001, P = 0.007, 
and P < 0.001, respectively).
Descriptive statistics of APP concentrations and 
NAGase activities in milk samples from clinical mas-
Table 1. Bacterial DNA quantities of udder pathogens detected in 226 milk samples from cases of cows with naturally occurring clinical mastitis1 
Identified mastitis pathogen (n = 443)
% of all DNA-positive 
milk samples 
(n = 226)
No. (%); mean Ct value2
+ ++ +++ 
Staphylococcus aureus (n = 49) 21.6 12 (24.4); 33.9 19 (38.7); 27.1 18 (36.7); 21.9
CNS (n = 91) 40.2 78 (85.7); 34.6 12 (13.1); 28.3 1 (1.1); 19.3
Streptococcus agalactiae (n = 12) 5.3 2 (16.6); 26.3 6 (50.0); 29.4 4 (33.3); 17.1
Streptococcus dysgalactiae (n = 33) 14.6 14 (42.4); 34.1 17 (51.5); 25.7 2 (6.1); 16.3
Streptococcus uberis (n = 98) 43.3 33 (33.6); 35.0 29 (29.6); 27.3 36 (36.7); 18.1
Trueperella pyogenes (n = 34) 15.0 24 (70.5); 35.1 5 (14.7); 25.1 5 (14.7); 19.4
Corynebacterium bovis (n = 53) 23.4 50 (94.3); 33.7 3 (5.7); 24.6 0
Enterococcus spp. (n = 4) 1.7 4 (100); 35.6 0 0
Escherichia coli (n = 67) 29.6 19 (28.3); 35.6 30 (44.8); 30.2 18 (26.8); 18.5
Klebsiella spp. (n = 2) 0.9 2 (100); 32.5 0 0
1+ = small quantities of bacterial DNA [range of cycle threshold (Ct) values: 28.3–37]; ++ = intermediate quantities of bacterial DNA (range 
of Ct values: 22.1–33.7); +++ = large quantities of bacterial DNA (range of Ct values: 13.4–27.4).
2Cycle threshold values of each pathogen were based on the quantity of bacterial DNA.
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titis is presented in Table 2. Associations between the 
concentrations of APP and NAGase activities in the 
milk and the PCR results are presented in Tables 3, 4, 
and 5. Concentrations of Hp and MAA and NAGase 
activity in the milk were not affected by farm, lactation 
number, or DIM (P > 0.05; data not shown). The af-
fected quarter (fore or hind) did not affect the Hp con-
centrations or the NAGase activities in milk (P > 0.05; 
data not shown). Significantly higher concentrations of 
MAA were found in the hind quarters compared with 
the fore quarters (Table 3).
Haptoglobin and MAA concentrations and NAGase 
activity in the milk were significantly higher when E. 
coli ++ and +++ or Strep. dysgalactiae ++/+++ were 
detected, compared with all other milk samples where 
these species were not detected. In addition, a small 
quantity (+) of E. coli in milk samples was associated 
with an elevated NAGase activity and MAA concentra-
tion. The presence of T. pyogenes at high levels in milk 
samples caused a significant elevation in Hp concentra-
tion, as well as an increased NAGase activity in the 
milk (P < 0.001 and P < 0.001, respectively) compared 
with milk samples without T. pyogenes. However, no 
association between the MAA concentration and the 
presence of T. pyogenes was found (P > 0.05; data not 
shown). Milk samples containing DNA from C. bovis or 
Table 2. Concentrations of milk amyloid A (MAA), haptoglobin (Hp), and N-acetyl-β-d-glucosaminidase (NAGase) activity in milk samples 
from cows with clinical mastitis (n = 147)1 
Pathogen
Median (minimum; maximum) value
MAA (mg/L) Hp (mg/L)
NAGase activity  
(pmol of 4-MU/min  
per microliter)2
Staphylococcus aureus (n = 18) 35.8 (6.7; 1,500) 201.1 (59.0; 756.2) 22.5 (2.7; 24.5)
CNS3 (n = 11) 29.2 (8.5; 1,500) 123 (59.0; 775.5) 11.86 (6.6; 24.5)
Streptococcus agalactiae (n = 4) 53.5 (28.9; 735.7) 295.5 (172.1; 506.1) 20.6 (6.6; 24.5)
Streptococcus dysgalactiae (n = 19) 147.6 (7.2; 905.2) 248.9 (74.8; 1,118.2) 20.8 (3.28; 24.5)
Streptococcus uberis (n = 36) 53.1 (4.5; 1,500) 385.6 (59.0; 970.3) 24.5 (3.36; 24.5)
Trueperella pyogenes (n = 10) 25.6 (0.95; 348.9) 618.5 (5.0; 1,155.8) 24.5 (1.73; 24.5)
Corynebacterium bovis4 (n = 4) 12.4 (0.09; 107.3) 95.8 (59.0; 108.6) 9.9 (0.5; 14.7)
Escherichia coli (n = 18) 394.1 (1.75; 1,500) 575.4 (59.0; 1,288.1) 24.5 (2.5; 24.5)
PCR negative (n = 27) 23.2 (7.4; 152.2) 164.1 (59.0; 548.3) 9.2 (1.3; 24.5)
1Only milk samples with 1 bacterial species only or 1 bacterial species in large quantity (+++) are included in the table.
24-MU = 4-methyl-umbelliferon.
3Milk samples where only bacterial DNA of small/intermediate quantity (+/++) of CNS was detected.
4Milk samples where only bacterial DNA of C. bovis +/++ was detected.
Table 3. Final generalized linear mixed model (GLMM) of associations between the concentration of milk amyloid A (MAA) in the milk and 
the pathogens detected with PCR (n = 253) from cows with naturally occurring clinical mastitis 
Variable1 Estimate2 95% CI P-value
Wald test  
(P-value)
Quarter
 Fore quarters (n = 102) 0
 Hind quarters (n = 179) 0.539 0.176; 1.011 0.005
Escherichia coli <0.001
 E. coli negative3 (n = 186) 0
 + (n = 19) 0.857 0.104; 1.610 0.026
 ++ (n = 30) 0.636 −0.025; 1.299 0.059
 +++ (n = 18) 1.68 0.843; 2.525 0.000
Streptococcus dysgalactiae 0.001
 Strep. dysgalactiae negative (n = 220) 0
 + (n = 14) 0.124 −0.737; 0.985 0.788
 ++/+++ (n = 19) 1.386 0.635; 2.136 0.000
Corynebacterium bovis
 C. bovis negative (n = 200) 0
 +/++ (n = 53) −0.664 −1.151; −0.140 0.012
Intercept 3.116 2.192; 4.040 0.000
1+ = small quantities of bacterial DNA; ++ = intermediate quantities of bacterial DNA; +++ = large quantities of bacterial DNA.
2Estimates are on a logarithmic scale.
3Number of milk samples not containing DNA from detected bacteria.
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a small quantity of DNA from CNS had a significantly 
lower concentration of APP and lower NAGase activity 
compared with all other milk samples where other spe-
cies were detected.
No interaction was detected in the models between 
minor (C. bovis and CNS) and major (E. coli, Strep. 
dysgalactiae, T. pyogenes, and Strep. uberis) pathogens. 
This means that any association between major patho-
gen DNA and the concentrations of the inflammatory 
markers was not influenced by the presence of minor 
pathogen DNA in the milk samples.
DISCUSSION
This study describes the associations between con-
centrations of APP in the milk and PCR-based bac-
teriological findings in cases of clinical mastitis. The 
amount of bacterial DNA detected in the samples from 
mastitis caused by certain species was associated with 
MAA and Hp concentrations and NAGase activity in 
the milk. The highest concentrations of MAA and the 
highest NAGase activities in milk were found in cows 
with large quantities of E. coli in their milk. This is in 
accordance with experimental studies showing a strong 
inflammatory response to E. coli (Hyvönen et al., 2006; 
Suojala et al., 2008). Wenz et al. (2010) found that the 
concentration of Hp was the highest in E. coli-induced 
mastitis compared with mastitis caused by environmen-
tal streptococci or CNS. However, even small quantities 
of E. coli resulted in elevated concentrations of MAA 
and increased NAGase activity in the milk. Experimen-
tal studies have shown that even a small quantity of 
E. coli can induce an acute inflammatory reaction in 
the udder (Frost et al., 1982). Escherichia coli bacteria 
are generally eliminated rapidly from the udder, but 
trigger a strong inflammatory reaction, which is mainly 
due to endotoxin (Burvenich et al., 2003). In practice, 
the time of sampling after the onset of clinical mastitis 
could also influence the quantity of DNA of E. coli in 
the milk. Sampling late during the course of infection 
could explain the small quantity of E. coli detected in 
bacteriological examination, despite a strong inflamma-
tory response.
Our findings support the results reported by Pyörälä 
et al. (2011), who found that higher concentrations of 
Hp and NAGase corresponded to the detection of T. 
pyogenes in mastitic milk samples but could establish 
no association between T. pyogenes and MAA. This 
could indicate that IMI due to T. pyogenes does not 
induce significant local production of MAA. Release of 
Table 4. Final generalized linear mixed model (GLMM) of associations between concentration of haptoglobin (Hp) in the milk and the 
pathogens detected with PCR (n = 253) from cows with naturally occurring clinical mastitis 
Variable1 Estimate2 95% CI P-value
Wald test  
(P-value)
Trueperella pyogenes <0.001
 T. pyogenes negative3 (n = 219) 0
 + (n = 24) −0.005 −0.017; 0.007 0.415
 ++/+++ (n = 10) −0.037 −0.055; −0.019 0.000
Escherichia coli <0.001
 E. coli negative (n = 186) 0
 + (n = 19) −0.004 −0.018; 0.009 0.532
 ++ (n = 30) −0.021 −0.033; −0.008 0.001
 +++ (n = 18) −0.029 −0.047; −0.014 0.000
Streptococcus uberis <0.001
 Strep. uberis negative (n = 164) 0
 + (n = 33) 0.002 −0.009; 0.012 0.784
 ++ (n = 29) −0.009 −0.021; 0.003 0.150
 +++ (n = 36) −0.023 −0.034; −0.012 0.000
Streptococcus dysgalactiae 0.008
 Strep. dysgalactiae negative (n = 220) 0
 + (n = 14) 0.006 −0.010; 0.021 0.465
 ++/+++ (n = 19) −0.020 −0.034; −0.007 0.003
CNS 0.10
 CNS negative (n = 162) 0
 + (n = 78) 0.008 0.0003; 0.016 0.040
 ++/+++ (n = 13) 0.008 −0.009; 0.024 0.358
Corynebacterium bovis
 C. bovis negative (n = 200) 0
 +/++ (n = 53) 0.013 0.005; 0.023 0.002
Intercept 0.089 0.072; 0.107 0.000
1+ = small quantities of bacterial DNA; ++ = intermediate quantities of bacterial DNA; +++ = large quantities of bacterial DNA.
2Estimates are on an inverse square root scale (negative estimate means higher concentration of Hp).
3Number of milk samples not containing DNA from detected bacteria.
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different APP may depend on the pathogens present. 
The major producers of Hp and NAGase in milk are 
neutrophils and epithelial cells, whereas only mammary 
gland epithelial cells appear to secrete MAA in cows 
with mastitis (Kitchen et al., 1984; Eckersall et al., 
2006; Lai et al., 2009). Epithelial damage may manifest 
differently in different infections, which in turn could 
affect MAA concentrations in the milk.
The presence of Staph. aureus in the udder increased 
the concentrations of APP and the NAGase activity 
in the milk less than other major pathogens, indicat-
ing a mild inflammatory response in this infection. In 
experimentally induced Staph. aureus mastitis, the con-
centrations of Hp and MAA ranged between 52 and 323 
mg/dL and between 34 and 286 mg/dL, respectively 
(Grönlund et al., 2003), and were lower than those 
found in experimentally induced Strep. uberis or E. coli 
mastitis (Pedersen et al., 2003; Suojala et al., 2008). 
Concentrations of Hp and MAA and NAGase activity 
in naturally acquired Staph. aureus mastitis were also 
lower than in streptococcal or E. coli mastitis (Pyörälä 
et al., 2011). In the present study, mastitis caused by 
Staph. aureus may have been very mild, which could 
explain the weak inflammatory response detected in 
the udder quarters. A small quantity of Staph. aureus 
DNA in the milk samples could also indicate that the 
bacteria were just skin contaminants and not the actual 
cause of the mastitis (Haveri et al., 2008).
In the present study, CNS and C. bovis were common 
bacterial species detected, mainly in small quantities, 
in milk samples positive for several species. C. bovis 
and CNS were the main pathogens detected using 
PCR from milk samples without growth (Taponen et 
al., 2009) and in the study by Koskinen et al. (2010) 
comparing conventional bacterial culturing and PCR 
in mastitis milk diagnostics. The frequent detection 
of these bacteria may be due to their extramammary 
origin. Corynebacterium bovis and CNS are generally 
considered to be opportunistic bacteria inhabiting teat 
skin and canals (Taponen et al., 2008). Nevertheless, 
the presence of CNS and C. bovis in the milk samples 
alone could increase concentrations of APP and NA-
Gase activity in the milk, indicating that these bacteria 
are able to invade the udder and induce an inflamma-
tory reaction. The PCR method allows the quantitative 
detection of udder pathogens and is especially useful 
Table 5. Random effects Tobit regression model of associations between N-acetyl-β-d-glucosaminidase (NAGase) activity in the milk and the 
pathogens detected with PCR (n = 253) from cows with naturally occurring clinical mastitis 
Variable1 Estimate2 95% CI P-value
Wald test  
(P-value)
Trueperella pyogenes 0.006
 T. pyogenes negative3 (n = 219) 0
 + (n = 24) 0.041 −0.721; 0.804 0.91
 ++/+++ (n = 10) 2.173 0.847; 3.499 0.001
Escherichia coli 0.002
 E. coli negative (n = 186) 0
 + (n = 19) 0.806 −0.025; 1.638 0.057
 ++ (n = 30) 1.247 0.486; 2.007 0.001
 +++ (n = 18) 1.464 0.500; 2.428 0.003
Streptococcus uberis <0.001
 Strep. uberis negative (n = 164) 0
 + (n = 18) −0.276 −0.934; 0.382 0.41
 ++ (n = 17) 0.159 −0.544; 0.861 0.66
 +++ (n = 30) 2.416 1.555; 3.276 0.000
Streptococcus dysgalactiae 0.003
 Strep. dysgalactiae negative (n = 220) 0
 + (n = 14) −0.966 −1.882; −0.049 0.039
 ++/+++ (n = 19) 1.100 0.274; 1.926 0.009
CNS <0.001
 CNS negative (n = 162) 0
 + (n = 78) −0.908 −1.390; −0.425 0.000
 ++/+++ (n = 13) −1.239 −2.162; −0.316 0.009
Corynebacterium bovis
 C. bovis negative (n = 200) 0
 +/++ (n = 53) −1.323 −1.855; −0.791 0.000
PCR positive (n = 226) 0
PCR negative (n = 27) −0.918 −1.687; −0.149 0.019
Intercept 3.116 2.018; 4.214 0.000
1+ = small quantities of bacterial DNA; ++ = intermediate quantities of bacterial DNA; +++ = large quantities of bacterial DNA.
2Estimates are on a square root scale.
3Number of milk samples not containing DNA from detected bacteria.
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when bacteria are present in small quantities and may 
be undetectable using conventional methods. On the 
other hand, the high sensitivity of the PCR analysis 
and the methods used to collect milk samples can cause 
false-positive results, especially in large herds when 
many staff members are involved in the sampling. 
The presence of microbes in a milk sample does not 
necessarily prove that those microbes caused the IMI. 
Interpretation of PCR results can be challenging and 
needs more guidance, even though PCR-based diagnos-
tics are already in routine use in some countries. In 
the interpretation of PCR results, detection of a single 
species, preferably in moderate or large quantities, or 
detection of one dominating species with some other 
species provides a likely bacteriological diagnosis. The 
final diagnosis of mastitis always requires a full comple-
ment of supporting information, such as knowledge 
of the clinical signs and inflammation in the quarter 
(Pyörälä, 2012).
In the present study, Hp performed better than 
MAA in describing bovine inflammatory response. A 
constant increase in concentrations of Hp in the milk 
along with increasing quantities of DNA (except CNS 
and C. bovis) was observed. Haptoglobin could, thus, 
be a better marker than MAA for indicating the local 
inflammatory response in clinical mastitis caused by 
different pathogens.
CONCLUSIONS
The quantity of bacterial DNA in milk samples was 
associated with concentrations of APP and NAGase 
activity in the milk. These indicators reflect the in-
flammatory reaction in the mammary gland, and their 
concentrations increased with increasing severity of 
mastitis. Concentrations of APP and NAGase activity 
in milk significantly differed between different mastitis-
causing bacterial species. Indicators of inflammation in 
milk, such as APP concentration and NAGase activity, 
may be useful to complete and support the bacterio-
logical diagnosis of mastitis.
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Abstract
Background: The goal of this study was to estimate the distribution of udder pathogens and their antibiotic
resistance in Estonia during the years 2007-2009.
Methods: The bacteriological findings reported in this study originate from quarter milk samples collected from
cows on Estonian dairy farms that had clinical or subclinical mastitis. The samples were submitted by local
veterinarians to the Estonian Veterinary and Food Laboratory during 2007-2009. Milk samples were examined by
conventional bacteriology. In vitro antimicrobial susceptibility testing was performed with the disc diffusion test.
Logistic regression with a random herd effect to control for clustering was used for statistical analysis.
Results: During the study period, 3058 clinical mastitis samples from 190 farms and 5146 subclinical mastitis
samples from 274 farms were investigated. Positive results were found in 57% of the samples (4680 out of 8204),
and the proportion did not differ according to year (p > 0.05). The proportion of bacteriologically negative samples
was 22.3% and that of mixed growth was 20.6%. Streptococcus uberis (Str. uberis) was the bacterium isolated most
frequently (18.4%) from cases of clinical mastitis, followed by Escherichia coli (E. coli) (15.9%) and Streptococcus
agalactiae (Str. agalactiae) (11.9%). The bacteria that caused subclinical mastitis were mainly Staphylococcus aureus
(S. aureus) (20%) and coagulase-negative staphylococci (CNS) (15.4%). The probability of isolating S. aureus from
milk samples was significantly higher on farms that had fewer than 30 cows, when compared with farms that had
more than 100 cows (p < 0.005). A significantly higher risk of Str. agalactiae infection was found on farms with
more than 600 cows (p = 0.034) compared with smaller farms. The proportion of S. aureus and CNS isolates that
were resistant to penicillin was 61.4% and 38.5%, respectively. Among the E. coli isolates, ampicillin, streptomycin
and tetracycline resistance were observed in 24.3%, 15.6% and 13.5%, respectively.
Conclusions: This study showed that the main pathogens associated with clinical mastitis were Str. uberis and
E. coli. Subclinical mastitis was caused mainly by S. aureus and CNS. The number of S. aureus and Str. agalactiae
isolates depended on herd size. Antimicrobial resistance was highly prevalent, especially penicillin resistance in
S. aureus and CNS.
Background
Bovine mastitis is the most common disease in dairy cows
worldwide, and antimicrobial therapy is the primary tool
for the treatment of mastitis. The prevalence of mastitis
pathogens and their antimicrobial resistance have been
investigated in numerous studies around the world. The
main pathogens that cause subclinical mastitis are coagu-
lase-negative staphylococci (CNS), Corynebacterium bovis
(C. bovis) and Staphylococcus aureus (S. aureus) [1-5].
Coliforms, Streptococcus uberis (Str. uberis) and S. aureus
are the pathogens isolated most frequently from clinical
mastitis samples [6-8]. Streptococcus agalactiae (Str. aga-
lactiae) has been largely eradicated from herds in Europe
[3], but in studies from the United States, 7.7% and 13.1%
of samples contained Str. agalactiae [9,10].
Several methods, such as disc diffusion, agar dilution,
broth dilution and broth microdilution are suitable for
in vitro antimicrobial susceptibility testing. Depending
on the study design and the methodology used, the anti-
microbial susceptibility of udder pathogens varies greatly
between studies. For example, studies from France and
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the UK have reported a high prevalence of penicillin-
resistant S. aureus (36.2%, 56%) [11,12], whereas a low
percentage of resistant isolates (4-9%) were found in the
Netherlands and Norway [13,14]. The streptococci that
cause mastitis are susceptible to b-lactam antibiotics;
however, resistance to macrolides and lincosamides is
notable [13,15]. In vitro resistance of E. coli to different
antimicrobials has been reported to be low [13,14,16,17].
National studies of mastitis prevalence provide impor-
tant information through the monitoring of national
udder health status, and they enable national guidelines
to be developed for the prudent use of antibiotics in
each country [18]. During recent decades, only broad-
spectrum antibiotics have been used for the treatment
of clinical mastitis in Estonia. For example, in the years
2006-2009, 15 different combinations of antibiotics were
available for use in 18 intramammary preparations that
were authorised by the Estonian State Medical Agency
[19]. Given that a large overview of udder pathogens
and their antibiotic resistance has not been performed
in Estonia, the goal of this study was to estimate the dis-
tribution of udder pathogens and their antibiotic resis-
tance during the years 2007-2009 in Estonia.
Methods
Sample collection
Milk samples were submitted to the Estonian Veterinary
and Food Laboratory during the period 2007-2009. Quar-
ter milk samples were collected from cows on Estonian
dairy farms by local veterinarians or farmers. Clinical mas-
titis was diagnosed when visible abnormalities of udder
(swelling) were detected or milk from a quarter had
abnormal viscosity (watery, thicker than normal), colour
(yellow, blood-tinged) or consistency (flakes or clots) [20].
Normal milk appearance, together with a positive Califor-
nia Mastitis Test result (score greater than 1), was used to
make a diagnosis of subclinical mastitis.
The samples were sent to the laboratory either for iso-
lation of the clinical mastitis pathogen and determina-
tion of its antimicrobial susceptibility or to determine
the reason for an increased somatic cell count.
Laboratory analysis
Bacterial species were identified using accredited metho-
dology based on the National Mastitis Council [21] stan-
dards. From each sample, 0.01 ml of milk was cultured
on blood-esculin agar and incubated for 48 h at 37°C.
The plates were examined after 24 and 48 h of incuba-
tion. A minimum of five colonies of the same type of
bacterium was recorded as bacteriologically positive, and
growth of more than two types of bacterial colonies was
categorised as mixed growth. No bacterial growth was
recorded when fewer than five colony-forming units
were detected during 48 h of incubation.
Once they had been isolated and identified, pure cul-
tures of udder pathogens were tested for antibacterial
susceptibility with the disc diffusion assay on Mueller-
Hinton agar. Testing was performed according to the
recommendation of the Clinical and Laboratory Stan-
dards Institute (CLSI) document M31-A2 in the years
2007-2008 and M31-A3 in 2009 [22,23]. Quality control
strains, S. aureus ATCC® 25923, E. coli ATCC® 25922,
Pseudomonas aeruginosa ATCC® 27853 and Streptococ-
cus pneumoniae ATCC® 49619, were included with
each batch of isolates tested. The antimicrobial suscept-
ibility of Gram-positive bacteria was tested with penicil-
lin, ampicillin, cephalothin, clindamycin, erythromycin,
gentamycin, trimethoprim/sulfa and tetracycline. The
antimicrobial susceptibility of Gram-negative bacteria
was tested with ampicillin, gentamycin, trimethoprim/
sulfa, tetracycline, enrofloxacin, streptomycin, neomycin
and cefaperazone. The list of antibiotics in susceptibility
testing may vary, different veteriarians preferred differ-
ent set of antibiotics in order to find accurate treatment
after getting the laboratory test results.
The criteria for the interpretation of zone diameter
used in this study are described in Table 1.
Data analysis
The farm, herd size and year were recorded and cate-
gorised before statistical analysis. A logistic regression
model with a random herd effect for the control of clus-
tering was used for all of the analyses in this study.
Odds ratios (OR) with 95% confidence intervals (95%
CI) were calculated. Statistical significance was set at
p ≤ 0.005.
The influence of milk samples with mixed growth or
no bacterial growth on the occurrence of clinical or sub-
clinical mastitis was assessed. Potential interactions (no
growth or mixed growth × year) were assessed in the
logistic regression model. The effects of herd size and
year on the pathogens that caused clinical and subclini-
cal mastitis were analysed. These analyses were con-
ducted using Stata 10.2 [24].
Results
Isolation of mastitis pathogens
During the study period, 3058 clinical mastitis samples
from 190 farms and 5146 subclinical mastitis samples
from 274 farms were investigated (Table 2).
Positive results were found in 57% of the samples
(4680 out of 8204), and this proportion did not differ
according to year (p > 0.05). The proportion of bacterio-
logically negative samples was 22.3% and that of mixed
growth 20.6%. There was a significantly higher chance
(OR = 1.15, 95% CI = 1.01, 1.33, p = 0.042) of finding
bacteriologically negative samples in presence of subcli-
nical mastitis (n = 1317, 25.6%) in comparison with
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clinical mastitis (n = 554, 16.8%). The probability of
obtaining mixed growth from milk samples was also sig-
nificantly higher (OR = 2.2, 95% CI = 1.9, 2.6, p <
0.001) if subclinical mastitis was found. The distribution
of bacterial species isolated from samples from cows
with clinical and subclinical mastitis is shown in
Table 3. Among the bacteriologically positive (n = 2016)
clinical mastitis samples, Str. uberis was the bacterium
isolated most frequently (n = 371; 18.4% of the positive
samples), followed by E. coli (n = 321; 15.9%) and Str.
agalactiae (n = 293; 11.9%). S. aureus (n = 532; 20%)
and CNS (n = 411; 15.4%) were the bacteria isolated
most commonly from milk in cases of subclinical masti-
tis, followed by Corynebacterium spp. (n = 395; 14.8%).
The probability of isolating S. aureus from milk sam-
ples was significantly higher on farms that had fewer
than 30 cows, when compared with farms with more
than 100 cows (OR = 0.2, 95% CI = 0.11, 0.53, p <
0.005). Also, there was a significantly higher risk of diag-
nosing Str. agalactiae on farms with more than 600
cows (OR = 17.6, 95% CI = 1.2, 259.1, p = 0.034) com-
pared with smaller farms.
Antimicrobial susceptibility testing
The percentage of S. aureus isolates resistant to penicil-
lin and ampicillin was 61.4% and 59.5%, respectively. In
addition, CNS showed resistance to penicillin and ampi-
cillin (38.5% and 34.4%), but resistance to erythromycin
and lincomycin was also common (14.9% and 17.6%).
Six isolates (3.8%) of S. aureus and three isolates (3.6%)
of CNS were resistant to cephalothin (Table 4).
All streptococci (Table 5) were susceptible to penicil-
lin, ampicillin and cephalothin, except for one isolate
of Str. uberis. Of the 90 isolates of Str. dysgalactiae,
19.8% were classified with intermediate susceptibility
and 32.2% with resistance to tetracycline. Of a total of
151 isolates of Str. uberis, 7.3% with intermediate sus-
ceptibility and 14.3% with resistance to tetracycline
were recorded. Among the E. coli isolates (Table 6),
the highest percentage of isolates showing intermediate
susceptibility and resistance were observed with ampi-
cillin, neomycin, streptomycin and tetracycline. E. coli.
was 98.4% susceptible to enrofloxacin and 100% to
cefaperazone.
Discussion
The results of the present study were based on an analy-
sis of milk samples submitted to an Estonian National
Veterinary Laboratory over a three-year period. The
laboratory protocols did not change during the study
period. Of the samples investigated, 22.3% were bacter-
iologically negative. Several other studies have also
demonstrated bacteriologically negative findings in
17.7-26.5% cases of clinical mastitis [12,25] and as many
as 28.7-38.6% of subclinical mastitis [12,26], which is in
line with our results. The possible reasons for bacterio-
logically negative findings in milk samples could be the
presence of antibacterial substances in the milk that
lead to a decrease in the viability of bacteria in the cul-
ture [27], or failures in conventional culture compared
with identification of bacteria using the real-time poly-
merase chain reaction [28].
Table 1 Zone diameter intepretive criteria
Disc content in μg Staphylococcus spp. Streptococcus spp. Enterococcus spp. Enterobacteriaceae spp.
S I R S I R S I R S I R
Ampicillin 10 μg ≥ 29 - ≤28 ≥ 26 19-25 ≤18 ≥ 17 - ≤16 ≥ 17 15-16 ≤14
Penicillin 10 μg ≥ 29 - ≥ 29 ≥24 - - ≥15 - ≤14 - - -
Cephalothin 30 μg ≥ ≤ - - -
Cefaperazone 75 μg - - - - - - - - - ≥21 16-20 ≤15
Clindamycin 2 μg ≥ 21 15-20 ≥ 14 ≥19 16-18 ≤15 - - - - - -
Erythromycin 15 μg ≥ 23 14-22 ≥ 14 ≥21 16-20 ≤15 - - - - - -
Gentamycin 10 μg ≥ 12 13-14 ≥ 15 ≥12 13-14 15≤ ≥10 7-9 ≤6 ≥ 12 13-14 ≥ 15
Tetracycline 30 μg ≥ 19 15-18 ≥ 14 ≥23 19-22 ≤18 ≥19 15-18 ≤14 ≥ 19 15-18 ≥ 14
Enrofloxacin 5 μg ≥ 20 15-19 ≤14
Trimethoprim/sulfa 1,25/23,75 μg ≥ 16 11-15 ≥ 10 ≥16 11-15 ≤10 ≥16 11-15 ≤10 ≥ 16 11-15 ≥ 10
Table 2 Distribution of milk samples according to herd
size
Clinical mastitis Subclinical mastitis
Farm size
category
Farms % Samples % Farms % Samples %
1 (1-30
cows)
54 28.4 98 3.2 41 15 86 1.7
2 (31-99
cows)
35 18.4 149 4.9 51 18.6 268 5.2
3 (100-299
cows)
40 21.1 378 12.4 53 19.3 541 10.5
4 (300-599
cows)
44 23.2 1472 48.1 80 29.2 2426 47.1
5 (> 600
cows)
17 8.9 961 31.4 49 17.9 1825 35.5
Total 190 100 3058 100 274 100 5146 100
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In the present study, E. coli and Str. uberis were the
pathogens isolated most frequently from clinical masti-
tis, while S. aureus, CNS and Corynebacterium spp.
caused mainly subclinical mastitis. The same results
were shown in an Estonian study ten years ago, where
C. bovis (47.5%), S. aureus (21%) and CNS (15.8%) were
the pathogens isolated most commonly from cases of
subclinical mastitis [29]. The isolation rate of Str. aga-
lactiae was surprisingly high in our study.
We found a strong association between the isolation
of Str. agalactiae and very large-scale farms. In total,
there are 98000 dairy cows in Estonia and the mean
herd size is 88 cows [30]. Rapid changes in management
style (from tie-stalls to free-stalls) have occurred during
the last eight years, which may explain the coexistence
of environmental pathogens together with Str. agalac-
tiae. Although teat disinfection and dry cow therapy is a
common routine on Estonian dairy farms, proper eradi-
cation programmes for Str. agalactiae have not been
employed. In contrast, an increased probability of find-
ing S. aureus was correlated with farms with fewer than
30 cows. The average age of cows on small farms was
5.3 years, compared with 4.3 years on farms on which
more than 300 cows were kept [30]. The culling policy
may be different, and the owners of smaller farms may
keep (possibly chronically infected) cows in the herd for
a longer period of time.
The disc diffusion method for in vitro antimicrobial
susceptibility testing was used in this study. This techni-
que is the most widely used method for determination
of the susceptibility of animal pathogens, especially in
clinical work when it is necessary to determine the cor-
rect treatment. The primary disadvantage of using this
method when monitoring development of resistance is
that outcomes are reported on a qualitative basis (sensi-
tive, intermediate, or resistant), and subtle changes in
susceptibility may not be apparent. Therefore any com-
parison with studies that use other methods of suscept-
ibility testing is not acceptable [31].
Generally in our study, the in vitro antimicrobial resis-
tance of the isolates examined from samples of clinical
Table 3 Distribution of bacterial species isolated from clinical and subclinical mastitis samples in 2007-2009













S. aureus 11.7 11.7 11.7 19.2 22.8 16.6
CNS 4.8 7.1 8.5 16.1 13.6 17.4
CPS* 3.8 3.3 1.6 4.6 2.8 5.1
Str. agalactiae 9.0 11.3 14.7 13.6 9.0 10.7
Str. dysgalactiae 8.0 7.8 7.2 3.6 4.0 5.6
Str. uberis 16.1 21.8 17.1 10.2 12.3 12.9
Str. spp 3.2 3.3 1.9 1.2 2.0 2.7
Lactococcus lactis 10.9 3.9 5.7 8.9 8.2 3.9
E. coli 14.4 16.6 16.5 1.6 2.0 3.8
Klebsiella spp. 7.0 1.3 2.3 0.7 0.6 0.9
Enterococcus spp. 1.3 2.3 1.1 1.5 2.8 4.2
Corynebacterium spp. 2.2 2.6 5.0 16.5 17.3 8.5
A. pyogenes 2.2 3.8 3.6 0.1 0.6 0.6
Pseudomonas spp. 1 0.3 0.3 0 0 0.6
Proteus spp. 0.2 0 0.2 0.4 0.1 0.6
Yeast 2.3 2 1.6 1.5 1.6 5.6
Other 1.8 0.9 1 0.3 0.3 0.3
Total 100% 100% 100% 100% 100% 100%
* CPS: coagulase-positive staphylococci (other than S. aureus).
Table 4 Antimicrobial susceptibility of staphylococci
isolated from bovine clinical mastitis
S. aureus CNS












Ampicillin10 μg 173 40.5 - 59.5 91 61.5 - 38.5
Penicillin10 μg 174 38.6 - 61.4 93 65.5 - 34.4
Cephalothin 30 μg 160 96.2 - 3.8 84 96.4 - 3.6
Clindamycin 2 μg 169 81.9 0 18.1 91 82.4 0 17.6
Erythromycin15 μg 83 95.2 0 4.8 47 85.1 0 14.9
Tetracycline 30 μg 147 95.9 0 4.1 86 88.4 0 11.6
Trimethoprim/sulfa 1.25/
23.75 μg
162 96.6 0 3.4 76 97.4 0 2.6
Gentamycin 10 μg 146 93.2 0 6.8 69 98.6 0 1.4
* Propotion of susceptible (S), intermediate susceptibility (I) and resistant (R)
isolates.
Kalmus et al. Acta Veterinaria Scandinavica 2011, 53:4
http://www.actavetscand.com/content/53/1/4
Page 4 of 7
127
mastitis were high. Isolates of S. aureus had an alarming
level of resistance to penicillin (61.4%) and ampicillin
(59.5%), whereas CNS exhibited a lower degree of resis-
tance to penicillin and ampicillin (38.5%; 34.4%). The
reported percentages for penicillin resistant S. aureus in
cases of clinical mastitis, detected by the disc diffusion
method, are 50.4% and 35.4% in the USA [10,32], 63.3%
in Turkey [33] and 12% in Northern Germany [34]. In
addition, cephalothin resistance among staphylococci was
found in our study. Although reports of methicillin-
resistant staphylococci causing bovine mastitis are rare,
those samples found in our study need further investiga-
tion in order to prove or exclude the presence of the
mecA gene. In the present study, both staphylococci and
streptococci showed resistance to erythromycin and lin-
comycin, but the figures for resistance in annual reports
from some other countries show a low prevalence of lin-
comycin and erythromycin resistance in S. aureus and
CNS [13,14,35]. Given that S. aureus and CNS were the
pathogens isolated most frequently from cases of subcli-
nical mastitis, one possible explanation for resistance to
several antibiotics may be the collection and submission
to the laboratory of milk samples from chronic clinical
mastitis (which demonstrate poor treatment efficacy).
Therefore, random sampling strategies should be used to
provide a good evaluation of antimicrobial susceptibility.
The level of resistance of E. coli and Klebsiella spp. was
high against all tested antimicrobials, except cefaperazone
and enrofloxacin. Coliforms are often resistant to more
than one antimicrobial [36,37], and the number of multi-
resistant strains may influence the resistance figures. Coli-
form bacteria isolated from cases of mastitis may reflect
the general situation of resistance in the herd and can be
considered more as an indicator of the bacteria present
than an indicator of specific pathogens from the udder
[36]. All of the bacterial species investigated in the present
study showed resistance to tetracycline. A possible expla-
nation for this phenomenon could be that tetracycline has
been the class of antimicrobial most widely used for treat-
ment of several infections for many years. In addition, tet-
racycline has been found in multiresistant patterns with
penicillin and streptomycin [33,37].
Statistical data from the Estonian State Medical
Agency confirmed [19] that alltogether 209880 single
intramammary syringes for lactating cows and 205648
for dry cow therapy were sold in the year 2009. Ampicil-
lin and cloxacillin combinations, cephalosporins with
aminoglycosides, and lincomycin with neomycin were
the most common choices for the treatment of mastitis
in lactating cows. For example, 255 grams of intramam-
mary lincomycin (pure antimicrobial) and 44.2 grams of
intramammary cephalosporins per thousand dairy cows
were sold for the treatment of clinical mastitis in 2009
[19]. However, only 73.4 grams of penicillin G was used
per thousand dairy cows for intramammary treatment of
clinical mastitis. The use of broad-spectrum antibiotics
and antibiotic combinations may influence the resistance
of mastitis pathogens. In addition, bacteriological exami-
nation of milk samples before treatment of clinical mas-
titis is not a common practice in Estonia. According to
Table 5 Antimicrobial susceptibility of streptococci isolated from bovine clinical mastitis
Str. agalactiae Str. dysgalactiae Str. uberis
Disc content in μg n S*
(%)












Ampicillin 10 μg 162 100 - 0 111 100 0 0 265 99.6 0 0.4
Penicillin 10 μg 168 100 - 0 111 100 0 0 267 99.6 0 0.4
Cephalothin 30 μg 143 100 - 0 101 100 0 0 254 99.6 0 0.4
Clindamycin 2 μg 161 91.9 1.9 6.2 115 92.2 0 7.8 273 92 1.4 6.6
Erythromycin 15 μg 77 96.1 2.6 1.3 60 88.3 5 6.7 134 89.6 2.2 8.2
Tetracycline 30 μg 151 78.1 7.3 14.6 90 48.9 18.9 32.2 234 79.9 3.4 19.7
Trimethoprim/sulfa
1.25/23.75 μg
140 93.6 0 6.4 103 99 0 1 223 95.9 0.9 3.2
Gentamycin 10 μg 143 63.6 11.9 24.5 88 88.6 0 11.4 210 71.9 9.5 18.6
* Propotion of susceptible (S), intermediate susceptibility (I) and resistant (R) isolates.
Table 6 Antimicrobial susceptibility of E. coli and
Klebsiella spp. isolated from bovine clinical mastitis
E. coli Klebsiella spp.












Ampicillin 10 μg 201 68.7 7.0 24.3 39 15.4 7.7 76.9
Cefaperazone75 μg 137 100 0 0 32 100 0 0
Tetracycline 30 μg 184 77.8 8.7 13.5 39 79.6 10.2 10.2
Trimethoprim/sulfa 1.25/
23.75 μg
191 84.3 3.7 12.0 40 97.5 0 2.5
Gentamycin 10 μg 161 94.3 2.5 2.2 40 95.0 0 5.0
Streptomycin 300
μg
154 78.6 5.8 15.6 37 73.0 8.1 18.9
Neomycin 30 μg 155 72.9 20.6 6.5 37 83.8 13.5 2.7
Enrofloxacin 5 μg 185 98.4 0 1.6 37 100 0 0
* Proportion of susceptible (S), intermediate susceptibility (I) and resistant (R)
isolates.
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the available data in Sweden, intramammary and intra-
muscular penicillin G [38] are used in over 80% of cases
for treatment of clinical mastitis, but the prevalence of
resistance of S. aureus to penicillins is only 7.1% [36]. In
Finland, penicillin G and some broad-spectrum b-lactam
antibiotics are used in the treatment of clinical mastitis,
but the prevalence of resistance in S. aureus is only 13%
[39]. Bacteriological examination before treatment is
common in both countries.
Considering these results, we can assume that the
main reason for the occurrence of a high number of
resistant strains in Estonian herds is the wide use of
broad-spectrum antimicrobials and the long-term pre-
sence of infected cows in herds.
Conclusion
This study showed that the main pathogens that caused
clinical mastitis were Str. uberis and E. coli. Subclinical
mastitis was caused mainly by S. aureus and CNS.
A relatively high number of isolates of Str. agalactiae
were cultured from both types of case. The number of
S. aureus and Str. agalactiae isolates depended on herd
size. Among the bacteria investigated, the prevalence of
antimicrobial resistance was extremely high, especially
penicillin resistance in S. aureus and CNS.
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